,Rank,NCTId,SecondaryId,StdAge,SecondaryIdLink,SecondaryIdType,SecondaryOutcomeDescription,SecondaryOutcomeMeasure,SecondaryOutcomeTimeFrame,SeeAlsoLinkLabel,SeeAlsoLinkURL,SeriousEventAssessmentType,SeriousEventNotes,SeriousEventOrganSystem,SeriousEventSourceVocabulary,SeriousEventStatsGroupId,SeriousEventStatsNumAffected,SeriousEventStatsNumAtRisk,SeriousEventStatsNumEvents,SeriousEventTerm,StartDate
0,1,['NCT04371159'],[],"['Adult', 'Older Adult']",[],[],[],"['Evaluation of the Velieve U.S. usability success rate, by potential lay users under actual use conditions.']",['11 months'],[],[],[],[],[],[],[],[],[],[],[],"['February 5, 2020']"
0,2,['NCT04474496'],[],"['Adult', 'Older Adult']",[],[],"['Respondents will be asked to rate their general health and mental health now and compared with before the COVID-19 outbreak', 'Respondents with type 2 diabetes will be asked to compare their current self-care behaviors with before the COVID-19 outbreak using multiple items, including the Summary of Diabetes Self-Care Activities (adapted to include retrospective pre-COVID-19 comparisons of behaviors)', 'Using Behavioral Risk Factor Surveillance System items and relevant items from the Summary of Diabetes Self-Care Activities, respondents will be asked to compare their current diet and physical activity behaviors with before the COVID-19 outbreak', 'Respondents will be asked to report whether they have been screened for COVID-19 (and how), whether they have been tested for COVID-19 (and how), whether they would accept a COVID-19 vaccine, and what specific actions they have taken to prevent being infected by COVID-19', 'Respondents will be asked to report which sources of information they use the most and trust the most to stay informed about COVID-19', 'Respondents will be asked to report how the COVID-19 outbreak has impacted their daily lives, including health concerns, impacts on family, and access to healthcare', 'Respondents will be asked to report how likely they feel they are to be infected, their chances of dying if infected, how easy it is to avoid being infected, and how concerned they are with what could result from being infected (e.g., losing a job, infecting others, being isolated)']","['Effects of COVID-19 on general health status and mental health', 'Effects of COVID-19 on disease management', 'Effects of COVID-19 on diet and physical activity behaviors', 'COVID-19 screening, testing, and prevention', 'Trusted sources of COVID-19 information', 'Impacts of COVID-19 on daily life', 'COVID-19 attitudes, fears, and beliefs']","['Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline']",[],[],[],[],[],[],[],[],[],[],[],"['July 27, 2020']"
0,3,['NCT02801266'],['12-9103'],['Adult'],[],['Other Identifier'],[],"['Type of contraceptive method currently using (including none and dual use) as assessed by a questionnaire designed for this study (e.g., what method of birth control are you currently using).']",['six months to one year from initial clinic visit'],[],[],[],[],[],[],[],[],[],[],[],['October 2012']
0,4,['NCT01599390'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],"['Influenza vaccine content and effectiveness by season.', 'Influenza vaccine coverage by season.']","['From July 1997 to April 2009 (i.e., up to almost 12 years)', 'From July 1997 to April 2009 (i.e., up to almost 12 years)']",[],[],[],[],[],[],[],[],[],[],[],['July 2012']
0,5,['NCT00312702'],['HSRRB A-13732'],['Adult'],[],['Other Identifier'],"['Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84']",['Anti-LSA-1 Antibody Response in Titer Units'],"['days 0, 28, 42 (challenge day) and 84']",[],[],[],[],[],[],[],[],[],[],[],['April 2006']
0,6,['NCT00312663'],['HSRRB A-13734'],['Adult'],[],['Other Identifier'],"['Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84']","['Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84']","['Days 0, 28, 42, and 84']",[],[],[],[],[],[],[],[],[],[],[],['April 2006']
0,7,['NCT01153880'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],['Prescription for retapamulin and topical mupirocin'],['First same-day prescriptions for both medicines in database for each calendar year between Janaury 2007 and December 2011'],[],[],[],[],[],[],[],[],[],[],[],['December 2008']
0,8,['NCT02019732'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],"['Assessment of Influenza vaccine content and effectiveness by season.', 'Assessment of Influenza vaccine coverage by season and region.', 'Assessment of Influenza B vaccine mismatch (by region and season).']","['Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).', 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).', 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).']",[],[],[],[],[],[],[],[],[],[],[],['January 2013']
0,9,['NCT03972358'],[],['Adult'],[],[],"['Efficacy', 'Safety and side effects', 'Experiences, perceived advantages and disadvantages']","['Number of participants not pregnant at follow-up', 'Number of participants with adverse events and/or side effects', 'Perceived advantages and disadvantages of MMR as reported by participants during the exit interview']","['Up to 28 days after mifepristone administration', 'Up to 28 days after mifepristone administration', 'Up to 28 days after mifepristone administration']",[],[],[],[],[],[],[],[],[],[],[],['January 2020']
0,10,['NCT00948233'],['W81XWH-09-2-0033'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],[],[],['University of Texas MD Anderson Cancer Center Website'],['http://www.mdanderson.org'],[],[],[],[],[],[],[],[],[],['June 2009']
0,11,['NCT00026728'],['01-C-0073'],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],['NIH Clinical Center Detailed Web Page'],['http://clinicalstudies.info.nih.gov/detail/B_2001-C-0073.html'],[],[],[],[],[],[],[],[],[],['February 2001']
0,12,['NCT01211990'],['10-M-0192'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['August 31, 2010']"
0,13,['NCT02663219'],"['UM1AI068619', '11995']","['Child', 'Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=UM1AI068619&Fy=all'],"['U.S. NIH Grant/Contract', 'Other Identifier']","['comparison between those who enrolled', 'participant-administered questionnaire', 'participant-administered questionnaire', 'viral load and cd4 are the biomarkers for adherence']","['HIV prevalence', 'HIV viral load after enrollment', 'Number of times participants are linked to care', 'HCV status at baseline', 'HIV viral load at end of study', 'Baseline Demographics', 'CD4 status at baseline', 'Self-reported sexual risk behavior of unprotected anal intercourse, characteristics of 3 most recent partners) at baseline and 24 months', 'Antiretroviral adherence at 24 months']","['Up to 24 months', 'Up to 24 months measured at months 3, 6, 9, 12, 18 and 24', 'Up to 24 months', 'Up to 24 months', 'Up to 24 months', 'Up to 24 months', 'Up to 24 months', 'Up to 24 months', 'Up to 24 months']",['Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV- positive MSM in Baltimore: Mathematical Modelling for HPTN 078'],['https://www.hptn.org/sites/default/files/2016-10/R4P_slides_KM_078_modelling_181016_FINAL.pdf'],[],[],[],[],[],[],[],[],[],"['June 6, 2016']"
0,14,['NCT00121108'],[],['Child'],[],[],[],['Safety and tolerability of MEDI-524 will be assessed primarily by summarizing adverse events and serious adverse events occurring through Study Day 150.'],['Through Day 150'],[],[],[],[],[],[],[],[],[],[],[],['November 2004']
0,15,['NCT01861210'],"['R34MH086331', 'CVCTMSM']",['Adult'],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH086331&Fy=all'],"['U.S. NIH Grant/Contract', 'Other Identifier']",['Either or both partners reported that the relationship ended after their participation in the study'],['Relationship dissolution'],"['3 months, or at the time of followup survey']",[],[],[],[],[],[],[],[],[],[],[],['September 2010']
0,16,['NCT02911155'],['16-C-N141'],"['Adult', 'Older Adult']",[],[],"['Collect data on nuclear medicine procedures performed, radioisotopes used, related work and safety practices, and places of employment over time.', ""Collect badge doses from the nation's largest commercial dosimetry provider for use in estimating occupational radiation exposures.""]","['Administer questionnaire', 'Obtain badge doses']","['2016-2018', '2016-2019']",[],[],[],[],[],[],[],[],[],[],[],"['September 21, 2016']"
0,17,['NCT00724867'],['HGS1006-C1066'],"['Adult', 'Older Adult']",[],['Other Identifier'],"['Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (<0.5 nanograms per milliliter [ng/mL]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of <0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA >=30 International Units/milliliter [IU/mL]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligram per deciliter (mg/dL) and C4 <16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligrams per decilitre (mg/dL) and C4 <16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to <=7.5 mg/day from >7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with >= 50% reduction in proteinuria among participants with Baseline proteinuria >0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change >0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).', 'The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).', 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).']","['Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.', 'Percentage of Participants Achieving SRI Response at Indicated Time Points', 'Observed Anti-double Stranded DNA Levels at Indicated Time Points.', 'Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.', 'Observed Complement C3 and C4 Levels at Indicated Time Points', 'Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points', 'Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.', 'Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.', 'Observed B-cell Levels at Indicated Time Points.', 'Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.', 'Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points', 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point', 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints', 'Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point', 'Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points']","['Up to Week 392', 'Up to Week 440', 'Up to Week 432', 'Up to Week 432', 'Up to Week 440', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384']",[],[],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Reproductive system and breast disorders', 'Reproductive system and breast disorders', 'Reproductive system and breast disorders', 'Reproductive system and breast disorders', 'Reproductive system and breast disorders', 'Immune system disorders', 'Immune system disorders', 'Skin and subcutaneous tissue disorders', 'Skin and subcutaneous tissue disorders', 'Skin and subcutaneous tissue disorders', 'Congenital, familial and genetic disorders', 'Congenital, familial and genetic disorders', 'Endocrine disorders', 'Endocrine disorders', 'Eye disorders', 'Eye disorders', 'Investigations', 'Investigations', 'Investigations', 'Pregnancy, puerperium and perinatal conditions', 'Pregnancy, puerperium and perinatal conditions', 'Renal and urinary disorders']","['MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA', 'MedDRA']","['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['44', '7', '5', '5', '3', '3', '2', '2', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '22', '4', '3', '2', '2', '2', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '20', '12', '5', '2', '1', '1', '1', '1', '19', '3', '3', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '15', '3', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '15', '4', '3', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '13', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '11', '3', '1', '1', '1', '1', '1', '1', '1', '1', '10', '3', '1', '1', '1', '1', '1', '1', '1', '1', '1', '8', '2', '2', '1', '1', '1', '1', '7', '2', '1', '1', '1', '1', '1', '1', '1', '7', '3', '1', '1', '1', '1', '1', '7', '2', '2', '1', '1', '1', '5', '2', '1', '1', '1', '5', '4', '1', '1', '4', '2', '1', '1', '1', '2', '2', '2', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1']","['268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268', '268']",[],"['Any event', 'Cellulitis', 'Pneumonia', 'Pneumonia bacterial', 'Gastroenteritis viral', 'Pneumonia viral', 'Bacterial pyelonephritis', 'Bronchitis bacterial', 'Gastroenteritis', 'Septic shock', 'Appendicitis', 'Arthritis bacterial', 'Arthritis infective', 'Atypical pneumonia', 'Bacterial sepsis', 'Bronchiolitis', 'Cellulitis staphylococcal', 'Cellulitis streptococcal', 'Clostridium difficile colitis', 'Fungal skin infection', 'Genital herpes', 'Herpes zoster', 'Infected dermal cyst', 'Infected skin ulcer', 'Influenza', 'Lobar pneumonia', 'Lower respiratory tract infection', 'Oral candidiasis', 'Pelvic abscess', 'Perinephric abscess', 'Pharyngitis bacterial', 'Pyelonephritis', 'Staphylococcal infection', 'Staphylococcal skin infection', 'Streptococcal urinary tract infection', 'Sweat gland infection', 'Urinary tract infection bacterial', 'Any event', 'Osteonecrosis', 'Arthralgia', 'Back pain', 'Muscular weakness', 'Musculoskeletal chest pain', 'Musculoskeletal pain', 'Osteoarthritis', 'Bursitis', 'Flank pain', 'Fracture nonunion', 'Intervertebral disc degeneration', 'Myalgia', 'Myositis', 'Osteoporotic fracture', 'Pain in jaw', 'Rotator cuff syndrome', 'Synovial cyst', 'Temporomandibular joint syndrome', 'Any event', 'Non-cardiac chest pain', 'Pyrexia', 'Chest pain', 'Asthenia', 'Chest discomfort', 'Oedema', 'Oedema peripheral', 'Any event', 'Abdominal pain', 'Vomiting', 'Nausea', 'Abdominal adhesions', 'Constipation', 'Diarrhoea', 'Duodenal ulcer', 'Enterocolitis', 'Erosive oesophagitis', 'Food poisoning', 'Gastric ulcer', 'Gastrointestinal haemorrhage', 'Gastrooesophageal reflux disease', 'Haemorrhoidal haemorrhage', 'Ileus', 'Large intestine perforation', 'Large intestine polyp', 'Lower gastrointestinal haemorrhage', 'Oesophageal spasm', 'Oesophageal ulcer haemorrhage', 'Pancreatitis acute', 'Small intestinal obstruction', 'Any event', 'Procedural haemorrhage', 'Fall', 'Post procedural complication', 'Alcohol poisoning', 'Comminuted fracture', 'Femoral neck fracture', 'Laceration', 'Meniscus injury', 'Muscle rupture', 'Overdose', 'Pneumothorax traumatic', 'Post procedural haematoma', 'Procedural pain', 'Toxicity to various agents', 'Wound', 'Wound dehiscence', 'Any event', 'Syncope', 'Headache', 'Hypoaesthesia', 'Paraesthesia', 'Amnesia', 'Cerebrovascular accident', 'Convulsion', 'Dizziness', 'Intracranial aneurysm', 'Loss of consciousness', 'Metabolic encephalopathy', 'Migraine', 'Posterior reversible encephalopathy syndrome', 'Transient ischaemic attack', 'Any event', 'Intraductal proliferative breast lesion', 'Uterine leiomyoma', 'Extranodal marginal zone B-cell lymphoma (MALT type)', ""Hodgkin's disease"", 'Malignant melanoma in situ', ""Non-Hodgkin's lymphoma"", 'Non-small cell lung cancer', 'Oestrogen receptor positive breast cancer', 'Ovarian cancer metastatic', 'Parathyroid tumour benign', 'Thyroid adenoma', 'Any event', 'Pulmonary embolism', 'Acute respiratory failure', 'Asthma', 'Chronic obstructive pulmonary disease', 'Haemoptysis', 'Hypoxia', 'Pleural effusion', 'Pleurisy', 'Respiratory failure', 'Any event', 'Hypertension', 'Hypertensive crisis', 'Hypotension', 'Jugular vein thrombosis', 'Lupus vasculitis', 'Malignant hypertension', 'Orthostatic hypotension', 'Peripheral ischaemia', ""Raynaud's phenomenon"", 'Subgaleal haematoma', 'Any event', 'Dehydration', 'Hypoglycaemia', 'Electrolyte imbalance', 'Hypercalcaemia', 'Hyperkalaemia', 'Hypokalaemia', 'Any event', 'Acute myocardial infarction', 'Angina pectoris', 'Atrial fibrillation', 'Cardiac failure congestive', 'Coronary artery disease', 'Hypertensive heart disease', 'Mitral valve disease', 'Palpitations', 'Any event', 'Depression', 'Anxiety', 'Dysthymic disorder', 'Mental status changes', 'Suicidal ideation', 'Suicide attempt', 'Any event', 'Lupus nephritis', 'Renal failure acute', 'Calculus ureteric', 'Hypertonic bladder', 'Nephrolithiasis', 'Any event', 'Leukopenia', 'Anaemia of chronic disease', 'Iron deficiency anaemia', 'Thrombocytopenia', 'Any event', 'Cholelithiasis', 'Cholecystitis', 'Cholecystitis acute', 'Any event', 'Uterovaginal prolapse', 'Benign prostatic hyperplasia', 'Cystocele', 'Menorrhagia', 'Any event', 'Drug hypersensitivity', 'Any event', 'Drug eruption', 'Systemic lupus erythematosus rash', 'Any event', 'Spinocerebellar ataxia', 'Any event', 'Thyroid mass', 'Any event', 'Vision blurred', 'Any event', 'Influenza A virus test positive', 'Influenza B virus test positive', 'Any event', 'Abortion spontaneous', 'Renal failure']",['August 2008']
0,18,['NCT03973905'],[],['Child'],[],[],"['Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second pregnancy trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'Vaccine effectiveness at preventing pertussis occurrence leading to hospitalization in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second, third trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.']","['Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (Before Pregnancy, During First or Second Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During First, Second or Third Trimester) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'Number of Pertussis Cases Leading to Hospitalization and Matched Controls in Infants Born to Mothers Vaccinated With Boostrix (Before Pregnancy, During First or Second, Third Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy']","['During the data collection period (from 1 January 2011 to 31 December 2014)', 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'During the data collection period (from 1 January 2011 to 31 December 2014)']",[],[],[],[],[],[],[],[],[],[],[],"['February 15, 2019']"
0,19,['NCT00340457'],['02-C-N051'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['November 15, 2001']"
0,20,['NCT02429284'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],['The central website for the U.S. CTEPH Registry'],['http://usctephregistry.com'],[],[],[],[],[],[],[],[],[],['April 2015']
0,21,['NCT02889263'],[],['Older Adult'],[],[],[],"['the most common diagnoses associated with the rehospitalizations for initial medical and surgical discharges', 'regional patterns of rehospitalization', 'the proportion of rehospitalized patients who received outpatient visits between the time of discharge and rehospitalization']","['30 days', '30 days', '30 days']",[],[],[],[],[],[],[],[],[],[],[],[]
0,22,['NCT03995745'],[],"['Adult', 'Older Adult']",[],[],"['viral load less than 400', 'electronic pill bottle openings by day']","['viral suppression by arm', 'medication adherence by arm', 'Recruitment rates by arm', 'Attrition rates by arm', 'Percent of patients that use electronic pill bottle', 'Completion rates of lab visit by arm', 'number of clinic visits by arm']","['approximately 3 months after enrollment', 'approximately 3 months after enrollment', 'approximately 3 months after enrollment', 'approximately 3 months after enrollment', 'approximately 3 months after enrollment', 'approximately 3 months after enrollment', 'approximately 3 months after enrollment']",[],[],[],[],[],[],[],[],[],[],[],"['May 16, 2019']"
0,23,['NCT00928694'],"['MK0767-031', '2009_606']",['Adult'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['February 2003']
0,24,['NCT02153996'],['14-I-0121'],"['Adult', 'Older Adult']",[],[],[],['Compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to age and sex matched individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.'],['5 years'],[],[],[],[],[],[],[],[],[],[],[],"['May 15, 2014']"
0,25,['NCT00413673'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['August 2001']
0,26,['NCT03867409'],"['5R01CA207689-02', 'OCR19177']","['Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R01CA207689-02&Fy=all'],"['U.S. NIH Grant/Contract', 'Other Identifier']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['November 5, 2018']"
0,27,['NCT04004260'],[],"['Adult', 'Older Adult']",[],[],"[""THS is a 10-item questionnaire that helps in determining how much of a patient's complaint about tinnitus is due to a hearing problem and how much is due specifically to the tinnitus. THS has three sections/subscales (A, B, and C). Section A consists of four items that address common tinnitus problems. Section B contains four items that address hearing. Section C, which includes two items, which focus on sound tolerance problem and ability to participate in group therapy. Responses for each item can range from 0 (not a problem) to 4 (very big problem). The total THS score can range from 0 to 40 (sections A and B range 0 to 16 and section C range from 0 to 8)."", 'TCQ is a 26-item questionnaire that assesses positive and negative cognitions associated with tinnitus. The first 13 items refer to negative thoughts and the second 13 items refer to positive thoughts. Responses are marked on a five-point Likert scale (0 to 4). The negative items (1-13) are scored 0-4, whereas the positive items (14-26) are reverse-scored: 4-0. The scoring procedure involves the simple addition of the number circled by the respondent for items 1-13 and the addition of reverse-scored items 14-26. The total score of the TCQ has a potential range from 0 to 104. A high score represents a greater tendency to engage in negative cognitions in response to tinnitus and low engagement in positive cognitions.', 'PHQ-9 is a 9-item questionnaire that assesses depression severity. Responses are marked on a four-point Likert scale (0 to 3). The total score can range from 0 to 27 with higher scores indicating more severe depression.', 'GAD-7 is a 7-item questionnaire that assesses the severity of anxiety. Responses are marked on a four-point Likert scale (0 to 3). The total score can range from 0 to 21 with higher scores indicating more severe anxiety.', 'ISI is a 7-item questionnaire that evaluates insomnia. Responses are marked on a five-point Likert scale (0 to 4). The total score can range from 0 to 28 with higher scores indicating more severe insomnia.', ""EQ-5D-5L is a 5-item questionnaire that evaluates health-related quality of life. Responses are marked on a five-point scale: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). The total score can range from 0 to 28 with higher scores indicating more severe insomnia. Possible health states is defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). EQ-5D-5L health states are converted into a single index 'utility' score using a scoring algorithm based on public preferences.""]","['Change in Tinnitus and Hearing Survey (THS)', 'Change in Tinnitus Cognition Questionnaire (TCQ)', 'Change in Patient Health Questionnaire (PHQ-9)', 'Change in Generalized Anxiety Disorder (GAD-7)', 'Change in Insomnia Severity Index (ISI)', 'Change in EuroQol EQ-5D-5L']","['8 weeks [Baseline; 2 month (last treatment session)]', '8 weeks [Baseline; 2 month (last treatment session)]', '8 weeks [Baseline; 2 month (last treatment session)]', '8 weeks [Baseline; 2 month (last treatment session)]', '8 weeks [Baseline; 2 month (last treatment session)]', '8 weeks [Baseline; 2 month (last treatment session)]']",['Study website'],['http://www.tacklingtinnitus.org'],[],[],[],[],[],[],[],[],[],"['March 1, 2020']"
0,28,['NCT04205877'],[],['Child'],[],[],"['Significant obstruction of the left pulmonary artery is defined as less than 30% flow to the left lung by lung perfusion scan or a peak instantaneous gradient in left pulmonary artery\n\n≥35 mmHg by echocardiogram if lung perfusion scan is not available or as determined by the interventional cardiologist based on angiographic appearance.', 'Significant obstruction of the aorta is defined as a gradient of ≥20 mmHg in the aortic isthmus by invasive aortic catheterization or a mean gradient ≥20 mmHg in the aortic isthmus by echocardiogram if invasive aortic catheterization is not available.']","['Significant obstruction of the left pulmonary artery', 'Significant obstruction of the aorta']","['6 months', '6 months']",[],[],[],[],[],[],[],[],[],[],[],"['January 1, 2020']"
0,29,['NCT01262079'],['HHSN272201000049I'],"['Child', 'Adult', 'Older Adult']",[],['Other Identifier'],['To evaluate influenza-specific T-cell responses to a panel of influenza strains across a broad age range of the U.S. population early as compared to late in the 2010-2011 influenza season.'],['Influenza-specific T-cell responses'],['2010-2011 influenza season'],['NIAID'],['http://www.niaid.nih.gov/Volunteer/VRC/Pages/default.aspx'],[],[],[],[],[],[],[],[],[],['December 2010']
0,30,['NCT00646438'],[],"['Adult', 'Older Adult']",[],[],[],['Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.'],['3 Years'],[],[],[],[],[],[],[],[],[],[],[],['March 2009']
0,31,['NCT00341588'],['02-C-N113'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['January 18, 2002']"
0,32,['NCT04562636'],['14380'],"['Adult', 'Older Adult']",[],['Other Grant/Funding Number'],"[""How much the message grabs one's attention. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct."", 'How much the messages make one feel scared. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'How much the messages make one think about the environmental/health harms caused by eating meat. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'How much one is likely to talk about the message with others in the next week. Measured using a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'How much one intends to reduce red meat consumption in the next 30 days. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.']","['Attention', 'Negative affect', 'Cognitive elaboration', 'Social interactions', 'Intention to reduce meat consumption']","['~10 minute computer survey immediately after seeing messages', '~10 minute computer survey immediately after seeing messages', '~10 minute computer survey immediately after seeing messages', '~10 minute computer survey immediately after seeing messages', '~10 minute computer survey immediately after seeing messages']",[],[],[],[],[],[],[],[],[],[],[],"['September 29, 2020']"
0,33,['NCT03924505'],['1R01DA046867-01'],"['Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01DA046867-01&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['September 3, 2019']"
0,34,['NCT02334462'],['15-I-0044'],['Adult'],[],[],[],['Anti -Pfs25 and Anti-Pfs230 antibody levels elicited by as measured by ELISA in U.S. adults and in exposed Malian adults'],"['U.S. Study: D. 14,28,42,84,140,196 Mali (Safety Arm: Same as the U.S. Mali (Functional Arm): D. 14,28,42,84,140,168,182,196,210,240,300,360,420,480,540,554,568,582,610,670,730']",[],[],[],[],[],[],[],[],[],[],[],"['January 7, 2015']"
0,35,['NCT03311295'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['April 3, 2018']"
0,36,['NCT03242278'],['XA1511US'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],['Baseline renal function'],['At baseline'],['Click here to find results for studies related to Bayer products.'],['http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/'],[],[],[],[],[],[],[],[],[],"['February 12, 2016']"
0,37,['NCT03683134'],[],"['Adult', 'Older Adult']",[],[],"['Measured in mmHg', 'Measured in kilograms (kg)', 'Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)', 'Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Measured in mg/dL', 'Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio', 'Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio', 'Measured in mg/dL', 'Measured in mg/dL', 'Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio', 'Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio', 'Fasting plasma glucose in mg/dL and fasting serum insulin in milliUnits (mU)/I will be used to calculate HOMA-IR as an indicator for insulin resistance.', 'Fasting plasma glucose in mg/dL and fasting serum insulin in mU/I will be used to calculate HOMA-IR as an indicator for insulin resistance.']","['Diastolic Blood Pressure Measurement', 'Change in Weight', 'Calculation of Body Mass Index (BMI) (kg/m∧2)', 'Calculation of BMI (kg/m∧2)', 'Concentration of fasted total cholesterol', 'Concentration of fasted total cholesterol', 'Concentration of fasted high-density lipoprotein (HDL) cholesterol', 'Concentration of fasted high-density lipoprotein (HDL) cholesterol', 'Concentration of fasted low-density lipoprotein (LDL) cholesterol', 'Concentration of fasted low-density lipoprotein (LDL) cholesterol', 'Concentration of fasted triglycerides', 'Concentration of fasted triglycerides', 'A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio', 'A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio', 'Concentration of fasted blood glucose', 'Concentration of fasted blood glucose', 'A calculation of waist (inches) to height (inches) ratio', 'A calculation of waist (inches) to height (inches) ratio', 'Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin', 'Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin']","['Change from at baseline weight to 6-weeks', 'Change from at baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 12-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 6-weeks', 'Change from baseline weight to 12-weeks']",[],[],[],[],[],[],[],[],[],[],[],"['January 23, 2017']"
0,38,['NCT04047316'],[],"['Child', 'Adult', 'Older Adult']",[],[],['The outcome of the secondary objective will be an anonymized database of digital skin lesion images and corresponding metadata and a set of high quality images amenable to clinician evaluation.'],['Develop a database of skin images with the new device with metadata and histopathology of excised lesions'],['1 year'],[],[],[],[],[],[],[],[],[],[],[],"['August 27, 2019']"
0,39,['NCT03952364'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['October 10, 2019']"
0,40,['NCT04021030'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['October 4, 2019']"
0,41,['NCT02959827'],[],['Child'],[],[],[],"['Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Year of Hypothyroidism Diagnosis) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Type of Iodine Contrast Exposure) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Race/Ethnicity) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Time From First Iodinated Contrast to First Hypothyroidism Event', 'Classification of Subclinical/Manifest Hypothyroidism by Type of Exposure', 'Classification of Hypothyroidism by Etiology']","['Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent']",[],[],[],[],[],[],[],[],[],[],[],"['October 15, 2016']"
0,42,['NCT02395536'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],"['Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment']",[],"['Cardiac disorders', 'Injury, poisoning and procedural complications', 'Nervous system disorders']","['MedDRA 18.1', 'MedDRA 18.1', 'MedDRA 18.1']","['EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001']","['1', '0', '1', '0', '1', '0']","['251', '231', '251', '231', '251', '231']","['1', '0', '1', '0', '1', '0']","['Atrioventricular block complete', 'Incision Site Haemorrhage', 'Cerebral Haemorrhage']","['March 30, 2015']"
0,43,['NCT03628235'],[],"['Adult', 'Older Adult']",[],[],"['For HDGECs and Companions: Understand how the traditional disease staging system, based on the TFC score, relates to a staging system based on resource utilization questionnaire and comorbid conditions developed in Divino et al. (2013)']","[""Identify the reasons for HDGEC and companion's unemployment or underemployment"", 'The proportion of Dual Role Companions, differentiated by HD stage of the companion', 'To understand traditional disease staging system based on total functional capacity (TFC)']","['12 months', '12 months', '12 months']",[],[],[],[],[],[],[],[],[],[],[],"['May 21, 2020']"
0,44,['NCT02787538'],[],"['Adult', 'Older Adult']",[],[],"['The MeiQ consists of 6 subscales and a total of 29 items. MeiQ was developed and tested in three different samples of patients with rheumatic conditions on their knowledge of medications.', 'The Partners in Health Scale is an 11-item measure designed to assess self-efficacy, knowledge of RA and treatment, and self-management behaviours such as taking medication appropriately and adopting a healthy lifestyle.', ""The HRU questionnaire was developed for both self and interviewer administration in people with arthritis and other chronic conditions. It consists of a series of open-ended questions about individuals' visits to health professionals, use of investigative tests, hospital visits, use of medications, purchases of adaptive aids, and estimable productivity loss incurred by the individual and their caregivers due to his/her health.""]","['Medication Education Impact Questionnaire (MeiQ)', 'Partners in Health Scale (PHS)', 'Health Resource Utilization (HRU) Questionnaire']","['Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2', 'Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2', 'Change measure (baseline score compared to after using the US-ANSWER-2 at Month 2)']",[],[],[],[],[],[],[],[],[],[],[],['January 2016']
0,45,['NCT01290393'],[],"['Child', 'Adult']",[],[],[],['Occurrence of other adverse pregnancy outcomes'],['This outcome measure will be recorded between zero and six weeks after end of pregnancy'],[],[],[],[],[],[],[],[],[],[],[],"['September 26, 2011']"
0,46,['NCT04263311'],[],"['Adult', 'Older Adult']",[],[],"['Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'Physician attitudes will be primarily assessed with data from brief surveys collected from the participating clinicians. Survey items with response scales will be designed to capture data on each of the research questions above. For instance, participants may be asked to respond on a five-point scale (from 1=strongly agree to 5=strongly disagree) to the following statement: ""CHWs are helpful tome"". The survey data come from a small sample (n=approximately 10) and are only intended to quantify descriptive information and not for extensive statistical analyses. The data will be tabulated and summarized descriptively to assess change in attitudes from baseline to 6 months.', 'At baseline, qualitative interviews of key informants will assess current satisfaction and usage of CHWs and organizational workflows. At follow-up the interviews will assess barriers and facilitators to the implementation and adoption process of the integrated intervention appropriates, fidelity to the interventions and the solicit recommendations for the replication and scalability of the intervention to other sites. Satisfaction and outcomes from the partnership and capacity building process will also be assessed. Audio-recordings and interview transcripts will be stripped of all identifying data. Using a qualitative approach, interview data will be transcribed and analysis will follow ""constant comparison"" analytic approach. Using ""thematic"" coding, initial set of codes will be created which will be reviewed by the CAB to ensure they are relevant and complete. The coded transcripts will be analyzed with ATLAS.ti, a qualitative data analysis software.']","['Change in Hemoglobin A1c (HbA1c)', 'Change in systolic blood pressure (SBP)', 'Change in diastolic blood pressure (DBP)', 'Change in body mass index (BMI)', 'Physicians Attitudes Regarding the Integrated Intervention', 'Barriers and Facilitators to Implementation Adoption and Implications for Scalability']","['6 months', '6 months', '6 months', '6 months', 'Baseline Visit, 6 months', 'Baseline Visit, 6 months visit, 12 month visit']",[],[],[],[],[],[],[],[],[],[],[],"['July 6, 2020']"
0,47,['NCT00875641'],[],['Child'],[],[],"['Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).']","['Incidence Rates of Kawasaki Disease Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Convulsions Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute Lower Respiratory Tract Infection (LRTI) Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of All-cause Mortality Among the HRV Cohort and Comparator Cohorts']","['60 days following each vaccination', '60 days following each vaccination', '60 days following each vaccination', '7 days following each vaccination', '30 days following each vaccination', '60 days following each vaccination']",[],[],[],[],[],[],[],[],[],[],[],"['April 20, 2009']"
0,48,['NCT03199846'],[],"['Adult', 'Older Adult']",[],[],"['Distribution of prescribing patterns by type of practice setting and melanoma patient volume', 'Patient Age at index date will be determined from Medical Records', ""Patient's sex will be determined from Medical Records"", 'Comorbidities will be determined using the Charlson Comorbidity Index (CCI)', 'Healthcare Coverage type will be determined using Medical Records', 'Melanoma Diagnosis Date will be determined using medical records', 'Date of advanced/ metastatic melanoma diagnosis will be determined using medical records', 'Diagnosis date-Date of Birth', 'Disease stage at time of diagnosis will be determined using medical records', 'Disease stage at subsequent visits will be determined using medical records', 'Eastern Cooperative Oncology Group (ECOG) status at Baseline will be determined using medical records', 'Eastern Cooperative Oncology Group (ECOG) status at Last Visit will be determined using medical records', 'Biomarker status will be determined using Medical Records', 'treatment-related adverse events will be determined using medical records', 'Date of death minus advanced/metastatic diagnosis date, censoring for LTF or end of observation', 'Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus advanced/metastatic diagnosis date, censoring for LTF or end of observation', 'Date of death minus index treatment start date, censoring for LTF or end of observation', 'Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus index treatment start date, censoring for LTF or end of observation']","['Distribution of prescribing patterns', 'Distribution of Patient Age at index date', ""Distribution of Patient's Sex at Index Date"", 'Distribution of Comorbidities at index date', 'Distribution of Healthcare Coverage type', 'Distribution of Diagnosis Date', 'Distribution of Advanced Diagnosis Date', 'Distribution of Age at Onset', 'Distribution of Disease stage at time of diagnosis', 'Distribution of Disease stage at subsequent visits', 'Distribution of ECOG status at Baseline', 'Distribution of ECOG status at Last Visit', 'Distribution of Biomarker status at baseline', 'Distribution of treatment-related adverse events', 'Distribution of Overall Survival (OS) from Advanced Diagnosis', 'Distribution of Progression-Free Survival (PFS) at Advanced Diagnosis', 'Distribution of Overall Response Rate (ORR)', 'Distribution of Overall Survival (OS) from Index Date', 'Distribution of Progression-Free Survival (PFS) at Index Date', 'Distribution of melanoma related HCRU']","['Approximately 16 months', 'at baseline', 'At Baseline', 'At Baseline', 'At Baseline', 'At Baseline', 'At Baseline', 'At Baseline', 'At Baseline', 'Approximately 16 months', 'At Baseline', 'Approximately 16 months', 'at baseline', 'Approximately 16 months', 'Approximately 16 months', 'Approximately 16 months', 'Approximately 16 months', 'Approximately 16 months', 'Approximately 16 months', 'Approximately 16 months']",['Investigator Inquiry Form'],['http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx'],[],[],[],[],[],[],[],[],[],"['October 25, 2016']"
0,49,['NCT04587245'],[],"['Child', 'Adult', 'Older Adult']",[],[],['Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.'],['Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.'],['12 months'],[],[],[],[],[],[],[],[],[],[],[],"['October 1, 2020']"
0,50,['NCT02773979'],['HHSN272201300019I'],['Adult'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['September 12, 2016']"
0,51,['NCT03274726'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['January 1, 1999']"
0,52,['NCT01283828'],[],['Adult'],[],[],[],"['Duration of carriage of C sordellii or C perfringens', 'Incidence of C. sordelli or C. perfringens carriage at 2 weeks after a negative test']","['2 years', '2 years']",[],[],[],[],[],[],[],[],[],[],[],['November 2010']
0,53,['NCT04191824'],[],"['Adult', 'Older Adult']",[],[],"['Change in urine microalbuminuria/proteinuria', 'Appropriate order of microalbuminuria/proteinuria tests', 'Change in appropriate diagnosis for stage 3 CKD', 'Appropriate diagnosis of CKD stage 3 and above', 'Change in appropriate diagnosis for any stage CKD', 'Appropriate diagnosis of all stage CKD']","['Change in urine microalbuminuria/proteinuria', 'Appropriate order of microalbuminuria/proteinuria tests', 'Change in appropriate diagnosis for stage 3 CKD', 'Appropriate diagnosis of CKD stage 3 and above', 'Change in appropriate diagnosis for any stage CKD', 'Appropriate diagnosis of all stage CKD']","['From baseline to 6 months', 'baseline to 6 months', 'baseline to 6 months', 'baseline to 6 months', 'Baseline to 6 months', 'Baseline to 6 months']",[],[],[],[],[],[],[],[],[],[],[],"['July 6, 2020']"
0,54,['NCT03197688'],[],"['Child', 'Adult', 'Older Adult']",[],[],"['To describe demographic characteristics of patients treated with Opsumit at beginning and during study time period', 'To describe clinical characteristics of patients treated with Opsumit at beginning and during study time period']","['Description of demographic characteristics of patients', 'Description of clinical characteristics of patients']","['Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018', 'Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018']",[],[],[],[],[],[],[],[],[],[],[],"['August 3, 2017']"
0,55,['NCT02813577'],[],"['Adult', 'Older Adult']",[],[],[],"['Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.', 'Number of Major Vascular Complications at 30 Days Post Index Procedure', 'Number of Deaths (All Causes) at 30 Days Post Index Procedure', 'Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure', 'Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure', 'Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure', 'Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure', 'Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.', 'Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure', 'Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline']","['30 days post index procedure', '30 days', '30 days post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure']",['Lutonix® 035 Drug Coated Balloon PTA Catheter Instructions For Use'],['http://www.bardpv.com/?portfolio=lutonix-035'],[],[],[],[],[],[],[],[],[],"['April 20, 2018']"
0,56,['NCT00666380'],"['A-14620 (HSRRB)', 'WRAIR 1417']",['Adult'],[],['Other Identifier'],['Functionality of antibodies elicited as measured by percent parasite growth inhibition in GIA against homologous (FVO) and heterologous (3D7) parasites'],['Percent parasite growth inhibition'],['Up to 112 days'],[],[],[],[],[],[],[],[],[],[],[],['April 2008']
0,57,['NCT01287247'],[],"['Adult', 'Older Adult']",[],[],[],['To collect and evaluate efficacy of Xeomin®(incobotulinumtoxinA) including onset and offset of effect as well as improvement of disease specific and global illness severity'],['Two treatment cycles (approximately 6 months/subject)'],[],[],[],[],[],[],[],[],[],[],[],['February 2011']
0,58,['NCT04163341'],[],"['Adult', 'Older Adult']",[],[],"['HIV RNA viral load <200 copies/mL', 'HIV RNA viral load <200 copies/mL', 'HRSA attendance measure: Engaged in care if attended >=2 HIV primary care visits >= 90 days apart in the 12 months after baseline.', 'Hamilton Rating Scale for Depression (HAM-D) score; minimum score is 0, maximum score is 52, with higher scores meaning a worse outcome.', 'Hopkins Symptom Checklist (HSCL) anxiety subscale score; minimum score is 1, maximum score is 4, with higher scores meaning a worse outcome.', 'Harvard Trauma Questionnaire (HTQ) score; minimum score is 1, maximum score is 4, with higher scores meaning a worse outcome.', 'Timeline Follow-Back', 'Kept visit proportion: Total number of kept visits divided by total number of missed plus kept visits']","['Suppressed HIV RNA viral load', 'Suppressed HIV RNA viral load', 'HIV appointment attendance', 'Depressive symptoms', 'Anxiety symptoms', 'Post-traumatic stress symptoms', 'Substance use symptoms', 'HIV appointment attendance']","['3 months post-baseline', '9 months post-baseline', 'From baseline to 12 months post-baseline', '3 months post-baseline', '3 months post-baseline', '3 months post-baseline', '3 months post-baseline', 'From baseline to 12 months post-baseline']",[],[],[],[],[],[],[],[],[],[],[],['September 2020']
0,59,['NCT02987335'],"['R01DK079974', 'R01DK069861']",['Adult'],"['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01DK079974&Fy=all', 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01DK069861&Fy=all']","['U.S. NIH Grant/Contract', 'U.S. NIH Grant/Contract']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],['December 2020']
0,60,['NCT02867722'],[],"['Adult', 'Older Adult']",[],[],[],"['Number of non-melanoma skin cancers at 1- and 5-years compared to the number of skin', 'Number of patients with treatment related adverse events as assessed by CTCAE v4.0', 'Measure patient satisfaction at 1- and 5- years using the Treatment Satisfaction Questionnaire for Medication']","['1 year and 5 years', '5 years', '1 year and 5 years']",[],[],[],[],[],[],[],[],[],[],[],['September 2016']
0,61,['NCT03276637'],[],"['Adult', 'Older Adult']",[],[],"[""Novel and adapted (Kaphingst, K.A., et al. 2012; Gray S.W., et al., 2014) survey measures will assess military healthcare providers' confidence in receiving, interpreting, and returning whole exome sequencing results"", ""Novel survey measures will assess active-duty patient-participants' perceptions and attitudes toward genomic sequencing"", 'Validated (Selim, A.J., et al. 2011) survey measures and military medical record review by trained genetic professional(s) will assess quality of life']","[""Change in military healthcare providers' confidence with genomic data"", ""Change in active-duty Airmen's perceptions and attitudes toward genomic sequencing"", ""Change in active-duty Airmen's health subsequent to introduction of genomic medicine""]","['Baseline, after education (within one month of baseline), 6 months prior to study completion', 'Baseline, 6 weeks after results disclosure', 'Baseline, 6 weeks after results disclosure, 1 year after results disclosure']",[],[],[],[],[],[],[],[],[],[],[],"['August 23, 2017']"
0,62,['NCT03192891'],[],"['Adult', 'Older Adult']",[],[],"['cardiac hospitalizations for unstable angina or heart failure, heart transplant, significant ventricular arrhythmias, and strokes']","['Non-fatal cardiac events', 'Cardiac event-weighted QALY']","['from time of study to the date 4 years following', 'from time of study to the date 4 years following']",[],[],[],[],[],[],[],[],[],[],[],"['March 1, 2017']"
0,63,['NCT03373045'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['February 27, 2018']"
0,64,['NCT04229212'],[],"['Adult', 'Older Adult']",[],[],"[""'C"", ""'C"", ""'C"", ""'C"", 'VAS score (0-10, while 0 is best, 10 is worst)', 'VAS score (0-10, while 0 is best, 10 is worst)', 'VAS score (0-10, while 0 is best, 10 is worst)', '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'Grade of hematoma (1-3, while 1 is best, 3 is worst)']","['body temperature', 'body temperature', 'body temperature', 'body temperature', 'Secondary outcome-Pain', 'Secondary outcome-Pain', 'Secondary outcome-Pain', 'width of the injured proximal thigh', 'width of the injured proximal thigh', 'width of the injured proximal thigh', 'width of the injured proximal thigh', 'wound condition', 'wound condition', 'wound condition', 'wound condition']","['preoperative', 'postoperative days 1', 'postoperative days 2', 'postoperative days 4', 'postoperative days 1', 'postoperative days 2', 'postoperative days 4', 'postoperative days 1', 'Intraoperation', 'postoperative days 2', 'postoperative days 4', 'Intraoperation', 'postoperative days 1', 'postoperative days 2', 'postoperative days 4']",[],[],[],[],[],[],[],[],[],[],[],"['December 11, 2018']"
0,65,['NCT02848781'],[],"['Adult', 'Older Adult']",[],[],"['Recurrent VT is defined as any appropriate ICD therapy (shock or ATP) or documented sustained monomorphic VT >30 seconds.', 'Cardiovascular rehospitalization is defined as a hospital admission after the randomized procedure for heart failure, procedure-associated complication, or arrhythmia-related causes during the follow-up period.']","['Freedom from recurrent VT', 'Freedom from cardiovascular rehospitalization', 'Freedom from all-cause mortality']","['2 years', '2 years', '2 years']",[],[],[],[],[],[],[],[],[],[],[],"['November 30, 2015']"
0,66,['NCT00385047'],"['A-13949', 'ETrack Protocol No. 104936', 'MAL-045', '#20060900']",['Adult'],[],"['Other Identifier', 'Other Identifier', 'Other Identifier', 'Other Identifier']",[],"['Anti-AMA-1 antibody titers during Immunization Phase', 'Anti-AMA-I antibody titers during Challenge Phase', 'Anti-AMA-I antibodies as percent parasite growth inhibition during Immunization Phase', 'Anti-AMA-I antibodies as percent parasite growth inhibition during Challenge Phase', 'Time to parasitemia development after primary challenge following administration of the FMP2.l/ASOIB and FMP2.l /AS02A']","['Up to 70 days', 'Up to 90 days', 'Up to 70 days', 'Up to 90 days', 'Up to 1 Year']",[],[],[],[],[],[],[],[],[],[],[],['September 2006']
0,67,['NCT02993120'],[],"['Adult', 'Older Adult']",[],[],"['Describe LDL-C levels and measurement patterns in subjects with clinical ASCVD', 'Describe subject characteristics', 'Describe subject understanding of CV risk', 'Describe subject goals of lipid management', 'Describe subject attitudes towards lipid lowering treatment (LLT)', 'The two levels of LDL-C that will be assessed are < 70 mg/dL and < 55 mg/dL.']","['LDL-C levels and measurement patterns', 'Subject Characteristics', 'Subject understanding of CV risk', 'Goals of Lipid Management', 'Attitudes towards lipid lowering treatment (LLT)', 'Percentage of Subjects Achieving Pre-Specified Levels Low-Density Lipoprotein Cholesterol (LDL-C) Before and After Educational Intervention', 'Number of Subjects who Experience an Intensification in Lipid-Lowering Therapy Before and After Educational Intervention', 'Percentage of Subjects on Optimal Medical Therapy Before and After Educational Intervention', 'Percentage of Physicians Stating a Specific Lipid Treatment Objective Before and After Educational Intervention']","['Through study completion, an average of 3 years', 'Through study completion, an average of 3 years', 'Through study completion, an average of 3 years', 'Through study completion, an average of 3 years', 'Through study completion, an average of 3 years', 'Up to 1 Year', 'Up to 1 Year', 'Up to 1 Year', 'Up to 1 Year']",['AmgenTrials clinical trials website'],['http://www.amgentrials.com'],[],[],[],[],[],[],[],[],[],"['December 6, 2016']"
0,68,['NCT03045120'],[],"['Adult', 'Older Adult']",[],[],[],"['echocardiography to assess left ventricular function', 'urinary protein excretion to assess early vascular endothelial changes', 'coronary calcium scoring to assess coronary artery narrowing', 'metabolic labs (Plasma Glucose, HbA1c, Fasting Lipids) for assessing the metabolic disease', 'safety and tolerability of first-line BCR-ABL TKIs in adults with CP-CML based on the number of treatment-related adverse events collected in the medical records', 'clinical outcomes as described by the number of deaths from clinical assessments of disease status and mutational analysis', 'clinical outcomes as described by the major molecular response from clinical assessments of disease status and mutational analysis', 'clinical outcomes as described by the cytogenetic response from clinical assessments of disease status and mutational analysis', 'time to development of clinical outcomes from baseline to time of clinical outcome event based on clinical assessments', 'description of treatment patterns based on the number of changes in treatment dosing, interruptions, changes in therapy, duration of therapy and treatment discontinuations through the management of adverse events and comorbid disease', 'description of the demographic and clinical patient characteristics associated with initial treatment choice and changes of treatment based on the medical records', 'measurement of serum biomarkers that are predictive of an increased risk for cardiovascular or metabolic disease']","['up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months', 'up to 24 months']","['Investigator Inquiry Form', 'FDA Safety Alerts and Recalls']","['http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx', 'http://www.fda.gov/Safety/Recalls/']",[],[],[],[],[],[],[],[],[],"['March 29, 2017']"
0,69,['NCT01154296'],['1RC2DA028973-01'],"['Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1RC2DA028973-01&Fy=all'],['U.S. NIH Grant/Contract'],"['Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts.', 'Self-reported continuous variables to determine number of unprotected (vaginal and/or anal) sex acts', 'Self-reported continuous variables to determine number of partners with whom the participant had (vaginal and/or anal) sex.', 'Self-reported continuous variables to determine number of partners with whom the participant had unprotected (vaginal and/or anal) sex.', 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts in which the participant reported using substances before the sex act.']","['Sexual Risk Behavior -- # of Sex Acts', 'Sexual Risk Behavior -- # of Unprotected Sex Acts', 'Sexual Risk Behavior -- # of Partners', 'Sexual Risk Behavior -- # of Unprotected Partners', 'Sexual Risk Behavior -- # of Sex Acts With Substance Use']","['6 months post randomization', '6 months post randomization', '6 months post randomization', '6 months post randomization', '6 months post randomization']",[],[],"['Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment']","['""General disorders"" selected as default; cause of death is unknown', '""General disorders"" selected as default; cause is homicide']","['General disorders', 'General disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Cardiac disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)']","['MedDRA (Unspecified)', 'MedDRA (Unspecified)', 'MedDRA (Unspecified)', 'MedDRA (Unspecified)', 'MedDRA (Unspecified)']","['EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001']","['1', '0', '1', '0', '1', '0', '0', '1', '0', '1']","['2505', '2507', '2505', '2507', '2505', '2507', '2505', '2507', '2505', '2507']","['1', '0', '1', '0', '1', '0', '0', '1', '0', '1']","['Death, cause unknown', 'victim of homicide, secondary to robbery', 'Cancer', 'Heart failure', 'Metastatic colon cancer']",['April 2010']
0,70,['NCT02857764'],['RRA-17578'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['February 15, 2016']"
0,71,['NCT00412568'],['WU #2335-99 (master protocol)'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['May 2004']
0,72,['NCT03353480'],[],['Adult'],[],[],['All observed or volunteered safety events regardless of treatment group or suspected causal relationship to the investigational product(s) will be reported during study.'],['Adverse Events'],"['Day 1 to Day 32 or early termination, plus at least 28 calendar days and up to 35 calendar days after the last administration of the investigational product']","['To obtain contact information for a study center near you, click here.']",['https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661212&StudyName=An+Open-label%2C+Randomized%2C+Single-dose%2C+3-way+Crossover+Bioequivalence+Study+Comparing+Azithromycin+250+Mg+Tablet+%28manufactured+At+Pfizer+Dalian%2C+China%29+With+Azithromycin+250+Mg+Tablet+%28manufactured+At+Pfizer+Barceloneta%2C+United+States%29+Under+Fasted+And+Fed+Conditions+In+Healthy+Chinese+Subjects'],[],[],[],[],[],[],[],[],[],"['December 20, 2017']"
0,73,['NCT00800267'],['A6641006'],"['Adult', 'Older Adult']",[],[],[],"['To examine, within treatment groups, the diurnal IOP reducing effect from baseline for all effect from baseline between the monotherapies latanoprost and timolol', 'To compare the diurnal IOP reducing effect from baseline between the monotherapies latanoprost and timolol at Week 26', 'To compared the number of treatment failures and patients withdrawn due to uncontrolled IOP from baseline to Week 26 between treatment groups', 'To describe the IOP development from baseline to Week 26 for all treatment groups', 'To compared the IOP reducing effect from baseline to Week 26 of the monotherapies with the IOP reducing effect from Week 26 to Week 52 of the fixed combination', 'To examine, within the fixed combination treatment group, the diurnal IOP reducing effect from baseline to Week 26 and Week 52', 'To follow the safety variables throughout the study periods.']","['6 months', '6 months', '6 months', '6 months', '6 months', '6 months', '6 months']","['To obtain contact information for a study center near you, click here.']",['https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=96TIPG005&StudyName=A%20study%20of%20glaucoma%20or%20ocular%20hypertension%20in%20patients%20within%20the%20United%20States.'],[],[],[],[],[],[],[],[],[],['July 1997']
0,74,['NCT00601835'],[],"['Child', 'Adult']",[],[],[],['Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.'],['28 Days post-vaccination'],"['http://www.sanofipasteur.com', 'Related Info']","['http://www.sanofipasteur.com', 'http://www.sanofi.com']","['Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment']",[],"['Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Congenital, familial and genetic disorders', 'Endocrine disorders', 'Eye disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Pregnancy, puerperium and perinatal conditions', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Respiratory, thoracic and mediastinal disorders', 'Reproductive system and breast disorders', 'Reproductive system and breast disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders']","['MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0', 'MedDRA 8.0']","['EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001']","['2', '1', '1', '0', '0', '2', '1', '2', '0', '1', '1', '1', '1', '0', '1', '0', '1', '2', '1', '0', '0', '1', '0', '1', '1', '1', '1', '0', '0', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '1', '0', '1', '0', '2', '4', '1', '0', '0', '1', '2', '0', '1', '0', '1', '1', '0', '1', '1', '0', '1', '0', '0', '1', '2', '0', '0', '1', '1', '1', '1', '0', '0', '1', '1', '0', '0', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '2', '0', '1', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '1', '1', '0', '1', '0', '0', '1', '1', '0', '1', '0', '1', '3', '0', '1', '0', '1', '0', '3', '0', '1', '0', '2', '1', '0', '1', '0', '1', '0', '1', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '0', '1', '1', '0', '0', '1', '0', '1', '0', '1', '1', '0', '0', '1', '0', '2', '1', '0', '1', '0', '2', '0', '1', '1', '0', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0']","['2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700', '2950', '700']","['2', '1', '1', '0', '0', '2', '1', '2', '0', '1', '1', '1', '1', '0', '1', '0', '1', '2', '1', '0', '0', '1', '0', '1', '1', '1', '1', '0', '0', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '1', '0', '1', '0', '2', '4', '1', '0', '0', '1', '2', '0', '1', '0', '1', '1', '0', '1', '1', '0', '1', '0', '0', '1', '2', '0', '0', '1', '1', '1', '1', '0', '0', '1', '1', '0', '0', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '2', '0', '1', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '1', '1', '0', '1', '0', '0', '1', '1', '0', '1', '0', '1', '3', '0', '1', '0', '1', '0', '3', '0', '1', '0', '2', '1', '0', '1', '0', '1', '0', '1', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '0', '1', '1', '0', '0', '1', '0', '1', '0', '1', '1', '0', '0', '1', '0', '2', '1', '0', '1', '0', '2', '0', '1', '1', '0', '1', '1', '0', '1', '1', '1', '0', '1', '0', '1', '0', '1', '0']","['Anaemia', 'Thrombocytopenia', 'Acute myocardial infarction', 'Angina pectoris', 'Atrial fibrillation', 'Cardiac failure congestive', 'Cardio-respiratory arrest', 'Cardiomyopathy', 'Myocardial infarction', 'Moebius II syndrome', 'Thyroid mass', 'Retinal artery occlusion', 'Abdominal pain', 'Colonic polyp', 'Dysphagia', 'Gastric ulcer perforation', 'Ileus', 'Inguinal hernia', 'Oesophageal achalasia', 'Peritonitis', 'Rectocele', 'Chest discomfort', 'Chest pain', 'Death', 'Non-cardiac chest pain', 'Cholecystitis', 'Cholecystitis chronic', 'Cholelithiasis', 'Bronchitis', 'Bronchitis acute', 'Cellulitis', 'Cystitis', 'Diverticulitis', 'Gangrene', 'Gastroenteritis', 'Infectious mononucleosis', 'Influenza', 'Localised infection', 'Pneumonia', 'Septic shock', 'Viral infection', 'Contusion', 'Femoral neck fracture', 'Fibula fracture', 'Head injury', 'Hepatic trauma', 'Hip Fracture', 'Joint dislocation', 'Post procedural haematoma', 'Rib fracture', 'Spinal compression fracture', 'Tibia fracture', 'Wound', 'Wrist fracture', 'Dehydration', 'Hyponatraemia', 'Arthropathy', 'Back Pain', 'Lumbar spinal stenosis', 'Musculoskeletal chest pain', 'Osteoarthritis', 'Rotator cuff syndrome', 'Scoliosis', 'Breast cancer', 'Colon Cacer', 'Hepatic neoplasm malignant', 'Metastatic squamous cell carcinoma', 'Pancreatic neoplasm', 'Paraganglion neoplasm malignant', 'Prostate cancer', 'Carotid artery stenosis', 'Cerebrovascular accident', 'Guillain-Barre syndrome', 'Post-traumatic headache', 'Transient ischaemic attack', 'Abortion spontaneous', 'Confusional state', 'Depression', 'Suicide attempt', 'Calculus ureteric', 'Cystocele', 'Haematuria', 'Nephrolithiasis', 'Urethral obstruction', 'Urinary incontinence', 'Urinary retention', 'Benign prostatic hyperplasia', 'Endometriosis', 'Pelvic prolapse', 'Asthma', 'Atelectasis', 'Chronic obstructive pulmonary disease exacerbated', 'Chronic obstructive airways disease', 'Dyspnoea', 'Pleural effusion', 'Arterial rupture', 'Deep vein thrombosis', 'Haematoma']",['May 2004']
0,75,['NCT01087905'],['1RC1CA144382-01'],"['Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1RC1CA144382-01&Fy=all'],['U.S. NIH Grant/Contract'],"['For cost analyses, we computed the costs of intervention per caller, the cost per quit based on the 6-month ITT 7-day PPA, and the incremental cost-effectiveness ratio (ICER. Intervention costs included direct costs associated with registration, provision of NRT and counseling (standard and MAC), and mailing of a quit guide (all participants) and a MAC information sheet (MAC participants only). Facility space, supplies, and physician supervision time were included in the call costs; research-related costs were excluded. ICER ratio is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; e.g., the ICER for the group that received 2 weeks of nicotine patch and nicotine gum = (213-178)/(.482-.384) = $357.']",['Incremental Cost-Effectiveness Ratio for 7-Day Point Prevalence Abstinence From Smoking at 26 Weeks Post-Quit by Nicotine Replacement Therapy (NRT) Group'],['26 weeks after the target quit smoking date'],['University of Wisconsin Center for Tobacco Research and Intervention'],['http://www.ctri.wisc.edu/'],[],[],[],[],[],[],[],[],[],['April 2010']
0,76,['NCT02616198'],[],"['Child', 'Adult']",[],[],"['The effect of different coatings on the clinical performance of the different glass ionomers tested was evaluated with United State Public Health Service criteria at baseline, 6-12-18 months and 6-years. For the evaluation 2 independent evaluators using dental problem and mirrors evaluated the resin coatings according to their retention, marginal adaptation, marginal discolouration, and colour match. There were 4 evaluation scores. Alpha meaning a perfect resin coating, Bravo meaning a coating partially effective but still clinically acceptable and Charlie and Delta meaning that the coating was partially to totally missed.']","['Effects of resin coating on the performance of glass ionomer cements according to the United State Public Health Service criteria regarding marginal adaptation, marginal discolouration, retention rate, and colour changes by 2 independent evaluators']",['6 years'],[],[],[],[],[],[],[],[],[],[],[],['January 2009']
0,77,['NCT00007540'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['April 1998']
0,78,['NCT02163525'],[],"['Adult', 'Older Adult']",[],[],"['Safety measures will be assessed by comparing the complication and reintervention rate for all three alternatives (GFA, Myomectomy, UAE).', 'Compare incidence costs of post discharge procedure-related complications and re-interventions we well as indirect cost factors defined as days to return-to-work, return to normal activities of daily living, and cost of care up to 60 months post discharge.', 'To compare fibroid symptom severity and quality of life scores at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) assessment tool.', 'Compare subjects menstrual bleeding pre-treatment and up to 3, 6, 12, 24, 36, 48, and 60 months post treatment using the Menorrhagia Impact Questionnaire (MIQ).', ""Assess the subject's satisfaction with her assigned procedure at 12 months post procedure using the Overall Treatment Effect questionnaire"", 'General health outcome evaluation at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the EuroQol (EQ-5D), a standardized instrument for use as a measure of health outcome', 'The incidence of acute and near-term serious complications following the GFA cases will also be analyzed by investigator-surgeon during the training and post training periods..']","['Assess the incidence and cost of post discharge procedure-related complications and reinterventions', 'Assess factors that influence indirect costs of the three treatment alternatives', 'Assess Uterine Fibroid Symptom Severity and Quality of Life (UFS-QoL) pre-treatment to post treatment in all treatment groups', 'Assess subjects menstrual bleeding using the MIQ', ""Assess subject's satisfaction with her treatment"", ""Assess the subject's general health outcome"", 'Assess the incidence of serious complications per investigator-surgeon during training and post training.']","['60 months', '60 months', '60 months', '60 months', '12 months', '60 months post procedure', '60 months']",[],[],[],[],[],[],[],[],[],[],[],['June 2014']
0,79,['NCT03310112'],[],"['Adult', 'Older Adult']",[],[],"['PHQ is used as a valid diagnostic and severity measure for depressive disorders.', 'GAD is used as a screening tool and severity measure for generalized anxiety disorder.', 'PCLM assesses the symptoms of Post-Traumatic Stress Disorder in military personnel.', 'PSQI assesses sleep quality and disturbances in seven ""component"" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.', 'AUDIT-C allows to identify people who are hazardous drinkers or have active alcohol use disorders.', 'BRS assesses the ability to bounce back or recover from stress.', ""PSS assesses the degree to which situations in one's life are viewed as stressful within the past month. Individual items assess feelings of stress, nervousness, irritation at life's hassles, and perceptions of one's own coping and control over a situation."", ""PANAS assesses positive and negative affect. It consists of a list of descriptors of positive (e.g., 'interested', 'enthusiastic') and negative (e.g., 'irritable', 'upset') affects. Items are rated on a 5-point scale (1 = very slightly or not at all, 5 = extremely), according to how participants feel. The Positive Affect scale reflects the extent to which a person feels enthusiastic, active, and alert; the Negative Affect scale reflects unpleasant mood states, such as anger, disgust, and fear."", 'Sunk Costs assesses resistance to framing, recognizing social norms, under/overconfidence, applying decision rules, risk perception, resistance to sunk costs, and path independence. A variant of this measure assessing resistance to sunk costs in a military context may be used.', 'CFQ assesses the frequency of committing minor, everyday mistakes.', '5FMQ assesses five major measures of mindfulness, including non-judgment of experience, non-reactivity to inner experience, observing emotions, acting with awareness, and describing feelings in words.', 'ERQ assesses individual differences in two emotion regulation strategies: expressive suppression and cognitive reappraisal.', 'CES assesses how many different experiences someone had while deployed and in combat.', 'RRS assesses two aspects of rumination: brooding and reflective pondering', 'SCQ assesses various facets of self-compassion', 'MWQ assesses common experiences related to distraction and mind-wandering.', 'Practice logs will be used to keep track of participants daily mindfulness practice.', 'Five questions regarding motivation to complete the testing session']","['Change in Patient Health Questionnaire depression scale (PHQ)', 'Change in Generalized Anxiety Disorder assessment (GAD-7)', 'Change in PTSD Checklist_Military (PCLM)', 'Change in the Pittsburgh Sleep Quality Index (PSQI)', 'Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)', 'Change in Brief Resilience Scale (BRS)', 'Change in Perceived Stress Scale (PSS)', 'Change in Positive and Negative Affect Scale (PANAS)', 'Change in Adult Decision-Making Competence scale (Sunk Costs questionnaire)', 'Change in Cognitive Failures Questionnaire (CFQ)', 'Change in Five-Facet Mindfulness Questionnaire (5FMQ)', 'Change in Emotion Regulation Questionnaire (ERQ)', 'Change in Combat Experiences Scale (CES)', 'Change in Rumination and Response Scale (RRS)', 'Change in Self-Compassion Questionnaire (SCQ)', 'Change in Mind Wandering Questionnaire (MWQ)', 'Practice logs', 'Motivation']","['Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Participants will complete paper practice logs tracking their daily practice (i.e., minutes) from the beginning of the MBAT through study completion (testing 3), which is an average of 8 weeks after beginning of the intervention.', 'Participants answer the motivation questions during the long-term post-intervention (testing 3) testing session, which is an average of 8 weeks from the baseline.']",[],[],[],[],[],[],[],[],[],[],[],"['October 9, 2017']"
0,80,['NCT02766634'],['C1121003'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],"['Time to maximum CD34+ count (Tmax[CD34+])', 'The concentration prior to dose on Day 5 (Ctrough)', 'Time to maximum serum filgrastim concentration (Tmax)', 'Elimination half-life (t1/2) from serum filgrastim concentrations following dose administration on Day 5']","['prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period', 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.', 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.', 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.']","['To obtain contact information for a study center near you, click here.']",['https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=ZIN-FIL-1501&StudyName=A+Randomized+Open-label%2C+Multiple-dose%2C+Crossover+Study+Evaluatig+The+Pharmacodynamics+And+Pharmacokinetics+Of+Filgrastim+Hospira+Compared+To+Us-approved+Neupogen+%28registered%29+Following+Subcutaneous+Administration+To+Healthy+Volunteers'],[],[],[],[],[],[],[],[],[],['March 2016']
0,81,['NCT02971709'],['0265'],"['Adult', 'Older Adult']",[],['Other Identifier'],"['Average potential UV exposure for a user of the passive recreation area assessed in standard erythemal units, based on measurements from a handheld UV meter performed by trained research assistants during assessment of the primary outcome.']",['Solar Ultraviolet Radiation Level'],['One-year'],[],[],[],[],[],[],[],[],[],[],[],['July 2010']
0,82,['NCT03801928'],['ONWARD'],"['Adult', 'Older Adult']",[],['Other Identifier'],"[""Crohn's disease remission indicated by Harvey Bradshaw Index score <5. Crohn's disease response if reduction of Harvey Bradshaw Score of ≥3 points from baseline."", 'Ulcerative colitis remission indicated by partial Mayo score <3 points. Ulcerative colitis response if reduction of partial Mayo score of ≥3 points from baseline.', 'All indications - Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score. Score ranges from 10-70, with higher scores being better.', 'All indications - Change in Quality of Life Visual Analog Scale (VAS), from baseline. VAS ranges from 0-100, with higher scores being better.', 'All indications - Treatment Satisfaction Questionnaire for Medication (TSQM) is a generic instrument with a total score and four domain scores: side effects (5 items), effectiveness (3 items), convenience (3 items), and global satisfaction (3 items).', 'For all indications - Count of health care related visits at each time point, including hospitalizations, Emergency Department visits, office visits and infusion clinic visits', 'All indications - Work Performance and Activity Impairment (WPAI) has 6 questions, related to the preceding 7 days. The questions consider hours missed from work due to health, hours missed because of other reasons (e.g., holidays), hours worked and productivity while working. Scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.']","[""Crohn's disease response and remission based on Harvey Bradshaw Index score"", 'Ulcerative colitis response and remission based on Partial Mayo score', ""Short Inflammatory Bowel Disease Questionnaire (SIBDQ) for Chron's disease and ulcerative colitis"", 'Quality of Life Visual Analog Scale (VAS)', 'Score on Treatment Satisfaction Questionnaire for Medication (TSQM)', 'Count of health care related resource utilizations at each study visit', 'Work Productivity and Activity Impairment (WPAI)']","['Baseline, 3 months, 6 months, 12 months', 'Baseline, 3 months, 6 months, 12 months', 'Baseline, 3 months, 6 months, 12 months', 'Baseline, 3 months, 6 months, 12 months', 'Baseline, 3 months, 6 months, 12 months', 'From Baseline through 12 months', 'Baseline, 3 months, 6 months, 12 months']","['To obtain contact information for a study center near you, click here.']",['https://pmiform.com/clinical-trial-info-request?StudyID=C1231006'],[],[],[],[],[],[],[],[],[],"['February 23, 2018']"
0,83,['NCT01641029'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['July 2013']
0,84,['NCT02128542'],[],"['Adult', 'Older Adult']",[],[],"['SVR4 was defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.', 'Viral breakthrough was defined as either:\n\nHCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment\nHCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values', 'Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA < LLOQ at end of treatment.', 'Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.']","['Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)', 'Percentage of Participants Experiencing Viral Breakthrough', 'Percentage of Participants Experiencing Viral Relapse', 'Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment']","['Posttreatment Week 4', 'Up to Posttreatment Weak 12', 'Up to Posttreatment Week 12', 'Pretreatment and Posttreatment Week 12']",[],[],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Blood and lymphatic system disorders', 'Cardiac disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'General disorders', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Musculoskeletal and connective tissue disorders', 'Nervous system disorders', 'Respiratory, thoracic and mediastinal disorders', 'Skin and subcutaneous tissue disorders']","['MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0', 'MedDRA Version 18.0']","['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1']","['66', '66', '66', '66', '66', '66', '66', '66', '66', '66', '66', '66']",[],"['Anaemia', 'Cardiac failure congestive', 'Nausea', 'Oesophageal varices haemorrhage', 'Chest pain', 'Bacteraemia', 'Endocarditis staphylococcal', 'Sepsis', 'Rhabdomyolysis', 'Drug withdrawal convulsions', 'Chronic obstructive pulmonary disease', 'Hyperhidrosis']",['June 2014']
0,85,['NCT00573976'],['2007-5854'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['September 2007']
0,86,['NCT00306007'],[],"['Child', 'Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['November 2005']
0,87,['NCT02766647'],['C1121002'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],"['Time to maximum serum filgrastim concentration (Tmax)', 'Elimination half-life (t ½)', 'Area under the serum filgrastim concentration versus time curve from time zero to the time of the last measurable concentration versus time curve from time zero to the time of the last measurable concentration (AUC0-t)', 'Clearance (CL)', 'Time to maximum ANC (Tmax[ANC])', 'Volume of distribution (Vd)']","['1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration', '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration']",[],[],[],[],[],[],[],[],[],[],[],['December 2015']
0,88,['NCT04460898'],[],"['Adult', 'Older Adult']",[],[],[],[],[],"['To obtain contact information for a study center near you, click here.']",['https://pmiform.com/clinical-trial-info-request?StudyID=A5481123'],[],[],[],[],[],[],[],[],[],"['January 4, 2019']"
0,89,['NCT00413517'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['November 2006']
0,90,['NCT02882100'],[],['Older Adult'],[],[],"['Change in activities of daily living (ADL) scores', 'Difference in mortality rate']","['Activities of daily living (ADL) scores', 'Mortality']","['up to 1 year', 'up to 1 year']",['FDA approves first seasonal influenza vaccine containing an adjuvant'],['https://wayback.archive-it.org/7993/20170111160747/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm'],[],[],[],[],[],[],[],[],[],['April 2016']
0,91,['NCT00533975'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['September 2007']
0,92,['NCT02109757'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['March 2014']
0,93,['NCT00959933'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['April 2001']
0,94,['NCT00960479'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['January 2001']
0,95,['NCT03266497'],[],"['Adult', 'Older Adult']",[],[],"['Quintile-, food-based dietary score assessing adherence to the DASH diet, which was developed as a dietary approach to prevent and treat hypertension. Components of the revised score include vegetables, fruit, whole grains, nuts and legumes, sodium, red and processed meat, and sugar-sweetened beverages.']",['Adapted DASH score'],['2003-2012'],[],[],[],[],[],[],[],[],[],[],[],['January 2003']
0,96,['NCT02207569'],[],"['Child', 'Adult', 'Older Adult']",[],[],"['Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.', 'Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.', 'VARC II composite safety endpoint rate includes percent freedom from the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)', 'Stage 2\n\nIncrease in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR\n\n>\n\nUrine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >\n\n1) Increase in serum creatinine to ≥300% (>3 x increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR\n\nUrine output <0.3 ml/kg/h for ≥24 h OR\n\n>\n\nAnuria for ≥12 h', 'Fatal bleeding (BARC type 5) OR\n\n>\n\nBleeding in a critical organs, such as intracranial, intraspinal,\n\n> intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR\n\n>\n\nBleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR\n\n>\n\nOvert source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* > (BARC type 3b)', 'Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure', 'Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.', 'Mean gradient by Doppler echocardiography.', 'Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR\n\n>\n\nAccess-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR\n\n>\n\nDistal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR\n\n>\n\nThe use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR\n\n>\n\nAny new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR\n\n>\n\nSurgery for access site nerve injury OR\n\n>\n\nPermanent access related nerve injury', 'Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2', 'Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.']","['Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR)', 'Coronary Artery Obstruction Requiring Intervention.', 'Percent VARC II Combined Safety Endpoint at 30 Days', 'Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy).', 'Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate', 'Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days', 'Percent Resheath and Recapture Success Rate', 'Hemodynamic Performance -Mean Gradient', 'Major Vascular Complication', 'Hemodynamic Performance - Aortic Valve Area', 'Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe']","['Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days', 'Assessed intra-procedurally', 'Assessed at baseline, 30 days, 6 months, and 1 year', 'Assessed at 30 days post-implantation', 'Assessed at baseline, 30 days, 6 months, and 1 year', 'Assessed at 30 days, 6 months, and 1 year']",[],[],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Eye disorders', 'Eye disorders', 'Eye disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Hepatobiliary disorders', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Investigations', 'Investigations', 'Investigations', 'Investigations', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Musculoskeletal and connective tissue disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Reproductive system and breast disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Skin and subcutaneous tissue disorders', 'Skin and subcutaneous tissue disorders', 'Skin and subcutaneous tissue disorders', 'Surgical and medical procedures', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders']","['MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0']","['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['36', '1', '1', '1', '2', '3', '1', '1', '15', '32', '3', '2', '4', '1', '4', '6', '1', '22', '3', '2', '1', '1', '1', '4', '1', '1', '1', '3', '1', '1', '1', '3', '2', '1', '1', '1', '2', '2', '1', '1', '1', '2', '12', '1', '1', '4', '1', '1', '4', '3', '2', '1', '1', '3', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '5', '1', '1', '1', '2', '1', '1', '12', '1', '1', '8', '1', '2', '9', '1', '1', '2', '1', '1', '1', '3', '4', '6', '1', '1', '2', '1', '1', '2', '2', '1', '2', '1', '2', '1', '1', '1', '2', '3', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '2', '1', '1', '1', '1', '10', '1', '2', '1', '1', '3', '1', '1', '1', '2', '1', '4', '1', '1', '4', '5', '1', '1', '1', '1', '2', '1', '1', '1', '8', '2', '1', '2', '4', '1', '2', '5', '1', '13', '1', '1', '1', '1', '1', '1', '1', '1', '2', '2', '1', '1', '1', '9', '16', '1', '1', '3', '1', '1', '1', '2', '1', '2', '3', '2']","['241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241', '241']","['39', '1', '1', '1', '2', '3', '1', '1', '16', '32', '3', '2', '4', '1', '4', '6', '1', '28', '3', '2', '1', '1', '1', '4', '1', '1', '1', '3', '1', '1', '1', '3', '2', '1', '1', '1', '2', '2', '1', '1', '1', '2', '12', '1', '1', '4', '1', '1', '5', '3', '2', '1', '1', '4', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '5', '1', '1', '1', '2', '1', '1', '16', '1', '1', '8', '1', '2', '9', '2', '1', '2', '1', '1', '1', '3', '4', '7', '1', '1', '2', '1', '1', '2', '2', '1', '2', '1', '2', '1', '1', '1', '2', '3', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '2', '1', '1', '1', '1', '12', '1', '2', '1', '1', '3', '1', '1', '1', '2', '1', '5', '1', '1', '4', '6', '1', '1', '1', '1', '3', '1', '1', '1', '11', '2', '1', '2', '6', '2', '2', '5', '1', '14', '1', '1', '1', '1', '18', '1', '1', '1', '2', '2', '1', '1', '2', '9', '16', '1', '1', '3', '1', '1', '1', '2', '1', '2', '3', '2']","['Anaemia', 'Haemolytic Anaemia', 'Iron Deficiency Anaemia', 'Splenic Infarction', 'Thrombocytopenia', 'Acute Myocardial Infarction', 'Angina Unstable', 'Aortic Valve Incompetence', 'Atrial Fibrillation', 'Atrioventricular Block Complete', 'Atrioventricular Block Second Degree', 'Bradycardia', 'Bundle Branch Block Left', 'Bundle Branch Block Right', 'Cardiac Arrest', 'Cardiac Failure', 'Cardiac Failure Acute', 'Cardiac Failure Congestive', 'Cardiac Perforation', 'Cardiogenic Shock', 'Coronary Artery Disease', 'Intracardiac Thrombus', 'Left Ventricular Dysfunction', 'Mitral Valve Incompetence', 'Myocardial Infarction', 'Myocardial Ischaemia', 'Nodal Rhythm', 'Pericardial Effusion', 'Pulseless Electrical Activity', 'Right Ventricular Dysfunction', 'Right Ventricular Failure', 'Sinus Bradycardia', 'Sinus Node Dysfunction', 'Stress Cardiomyopathy', 'Ventricular Asystole', 'Ventricular Fibrillation', 'Ventricular Tachycardia', 'Cataract', 'Glaucoma', 'Visual Impairment', 'Dysphagia', 'Gastric Ulcer', 'Gastrointestinal Haemorrhage', 'Gastrooesophageal Reflux Disease', 'Hiatus Hernia', 'Inguinal Hernia', 'Intestinal Ischaemia', 'Intestinal Obstruction', 'Retroperitoneal Haemorrhage', 'Chest Pain', 'Death', 'Device Deployment Issue', 'Device Dislocation', 'Implant Site Haemorrhage', 'Implant Site Pain', 'Lead Dislodgement', 'Oedema Peripheral', 'Systemic Inflammatory Response Syndrome', 'Cholecystitis', 'Cholecystitis Acute', 'Gallbladder Disorder', 'Abdominal Wall Abscess', 'Acquired Immunodeficiency Syndrome', 'Bronchitis', 'Cellulitis', 'Clostridium Difficile Colitis', 'Diverticulitis', 'Diverticulitis Intestinal Haemorrhagic', 'Gangrene', 'Incision Site Infection', 'Influenza', 'Osteomyelitis', 'Pneumonia', 'Pneumonia Staphylococcal', 'Postoperative Wound Infection', 'Sepsis', 'Septic Shock', 'Upper Respiratory Tract Infection', 'Urinary Tract Infection', 'Urosepsis', 'Ankle Fracture', 'Arterial Injury', 'Compression Fracture', 'Feeding Tube Complication', 'Femur Fracture', 'Hip Fracture', 'Incision Site Complication', 'Incision Site Haematoma', 'Incision Site Haemorrhage', 'Laceration', 'Pelvic Fracture', 'Seroma', 'Subdural Haematoma', 'Vascular Pseudoaneurysm', 'Blood Magnesium Decreased', 'Blood Pressure Increased', 'International Normalised Ratio Increased', 'Urine Output Decreased', 'Fluid Overload', 'Gout', 'Hyperglycaemia', 'Hypoalbuminaemia', 'Hypoglycaemia', 'Hypokalaemia', 'Hypomagnesaemia', 'Hyponatraemia', 'Hypovolaemia', 'Lactic Acidosis', 'Metabolic Acidosis', 'Arthralgia', 'Arthritis', 'Muscular Weakness', 'Osteoarthritis', 'Rotator Cuff Syndrome', 'Spinal Column Stenosis', 'Adenocarcinoma', 'Bladder Cancer', 'Breast Cancer', 'Chondrosarcoma', 'Colon Cancer', 'Colon Neoplasm', 'Small Intestine Adenocarcinoma', 'Squamous Cell Carcinoma', 'Brain Injury', 'Carotid Artery Stenosis', 'Cerebral Haemorrhage', 'Cerebral Infarction', 'Cerebrovascular Accident', 'Dizziness', 'Encephalopathy', 'Hemiplegia', 'Hypoxic-Ischaemic Encephalopathy', 'Ischaemic Stroke', 'Metabolic Encephalopathy', 'Partial Seizures', 'Speech Disorder', 'Syncope', 'Thalamic Infarction', 'Transient Ischaemic Attack', 'Delirium', 'Hallucination, Visual', 'Mental Disorder', 'Acute Kidney Injury', 'Haematuria', 'Nephrolithiasis', 'Renal Failure', 'Renal Infarct', 'Urinary Retention', 'Benign Prostatic Hyperplasia', 'Acute Pulmonary Oedema', 'Acute Respiratory Failure', 'Chronic Obstructive Pulmonary Disease', 'Dyspnoea', 'Epistaxis', 'Haemoptysis', 'Pleural Effusion', 'Pneumonia Aspiration', 'Pulmonary Hypertension', 'Pulmonary Oedema', 'Respiratory Depression', 'Respiratory Failure', 'Stridor', 'Diabetic Ulcer', 'Skin Ulcer', 'Subacute Cutaneous Lupus Erythematosus', 'Hospitalisation', 'Aortic Dissection', 'Aortic Dissection Rupture', 'Arteriosclerosis', 'Deep Vein Thrombosis', 'Femoral Artery Dissection', 'Femoral Artery Occlusion', 'Haematoma', 'Haemorrhage', 'Hypertension', 'Hypotension', 'Iliac Vein Occlusion', 'Intermittent Claudication', 'Labile Blood Pressure', 'Labile Hypertension', 'Malignant Hypertension', 'Orthostatic Hypotension', 'Peripheral Arterial Occlusive Disease', 'Peripheral Artery Dissection', 'Peripheral Artery Stenosis', 'Peripheral Ischaemia', 'Peripheral Vascular Disorder']",['August 2014']
0,97,['NCT02569632'],[],"['Adult', 'Older Adult']",[],[],"['Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3']",['Antibody repertoire to FHbp'],['1 year'],[],[],[],[],[],[],[],[],[],[],[],['January 2015']
0,98,['NCT02069925'],['1R01MH103831-01'],"['Child', 'Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH103831-01&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['February 1, 2014']"
0,99,['NCT03433131'],[],"['Adult', 'Older Adult']",[],[],[],[],[],['Program website to provide information to both prosective patients and physicians'],['http://thepeacenarcolepsyprogram.com'],[],[],[],[],[],[],[],[],[],[]
0,100,['NCT02746809'],[],"['Child', 'Adult', 'Older Adult']",[],[],"['VARC II composite safety endpoint includes the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)', 'Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details', 'Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details', 'Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details', 'Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details', 'Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details', 'Percentage of subjects with new permanent pacemaker implant at 30 days.', 'Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.\n\nSuccessful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.', 'Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory']","['Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days', 'Percentage of Participants With Life Threatening or Disabling Bleeding', 'Percentage of Participants With Major Vascular Complication', 'Percentage of Participants With Acute Kidney Injury: Stage 2 or 3', 'Percentage of Participants With Coronary Artery Obstruction', 'Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure', 'Percentage of Subjects With Permanent Pacemaker Implant at 30 Days', 'Percentage of Resheath and Recapture Success', 'Hemodynamic Performance Metrics - Mean Gradient', 'Hemodynamic Performance Metrics- Aortic Valve Area', 'Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace']","['30 days post-implantation', '30 days post-implantation', '30 days', '30 days', '30 days', '30 days', '30 days', 'Implant procedure', 'Baseline, 30 days, and 6 months', 'Baseline, 30 Days, and 6 Months', '30 days and 6 months']",[],[],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders', 'Eye disorders', 'Gastrointestinal disorders', 'General disorders', 'General disorders', 'General disorders', 'General disorders', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Infections and infestations', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Injury, poisoning and procedural complications', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Metabolism and nutrition disorders', 'Musculoskeletal and connective tissue disorders', 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Nervous system disorders', 'Psychiatric disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Renal and urinary disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders', 'Vascular disorders']","['MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0', 'MedDRA 10.0']","['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['2', '1', '1', '1', '8', '1', '1', '2', '1', '2', '1', '1', '1', '1', '1', '1', '2', '1', '1', '2', '1', '1', '1', '2', '4', '1', '1', '1', '1', '1', '1', '1', '1', '1', '2', '1', '1', '1', '1', '2', '1', '1', '1', '1', '4', '1', '1', '2', '1', '2', '1', '3', '1', '2', '2', '1']","['60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60', '60']","['2', '1', '1', '1', '8', '1', '1', '2', '1', '3', '1', '1', '1', '1', '1', '1', '2', '1', '1', '2', '1', '1', '1', '2', '4', '1', '1', '1', '1', '1', '1', '1', '1', '1', '2', '1', '1', '1', '1', '2', '1', '1', '1', '1', '4', '1', '1', '2', '1', '2', '1', '3', '1', '2', '2', '1']","['Anaemia', 'Coagulopathy', 'Acute Myocardial Infarction', 'Atrioventricular Block', 'Atrioventricular Block Complete', 'Atrioventricular Block First Degree', 'Bundle Branch Block Left', 'Cardiac Arrest', 'Cardiac Failure Acute', 'Cardiac Failure Congestive', 'Cardio-Respiratory Arrest', 'Cardiogenic Shock', 'Conduction Disorder', 'Nodal Rhythm', 'Pulseless Electrical Activity', 'Supraventricular Tachycardia', 'Ventricular Tachycardia', 'Vision Blurred', 'Rectal Haemorrhage', 'Chest Pain', 'Device Embolisation', 'Generalised Oedema', 'Pyrexia', 'Bronchitis', 'Pneumonia', 'Sepsis', 'Viral Infection', 'Arterial Injury', 'Compression Fracture', 'Concussion', 'Hip Fracture', 'Hyperglycaemia', 'Hypomagnesaemia', 'Malnutrition', 'Rhabdomyolysis', 'Lung Neoplasm Malignant', 'Cerebrovascular Accident', 'Dizziness', 'Hypoxic-Ischaemic Encephalopathy', 'Syncope', 'Transient Ischaemic Attack', 'Confusional State', 'Glomerulonephritis Membranous', 'Haematuria', 'Urinary Retention', 'Acute Respiratory Failure', 'Bronchiectasis', 'Pleural Effusion', 'Pulmonary Embolism', 'Pulmonary Oedema', 'Respiratory Failure', 'Deep Vein Thrombosis', 'Femoral Artery Dissection', 'Hypertension', 'Hypotension', 'Peripheral Ischaemia']",['June 2016']
0,101,['NCT00328380'],[],"['Adult', 'Older Adult']",[],[],[],['A secondary endpoints of this study include assessment of the differences between the 2 treatment groups based upon the proportion of subjects with TD during the 14-day Treatment Period.'],[],[],[],[],[],[],[],[],[],[],[],[],['December 2005']
0,102,['NCT04552535'],[],"['Adult', 'Older Adult']",[],[],[],[],[],['Related Info'],['http://www.mystudywindow.com'],[],[],[],[],[],[],[],[],[],"['May 8, 2020']"
0,103,['NCT03293875'],[],"['Adult', 'Older Adult']",[],[],"['strength of intentions to reduce HIV risk behaviors', 'perception of risk of contracting HIV', 'frequency with which participants engaged in HIV preventative behaviors', 'the extent to which participant has engaged in conversations with members of the social network about engaging in behaviors to prevent HIV']","['HIV risk reduction behavioral intentions (questionnaire)', 'HIV-related vulnerability beliefs (questionnaire)', 'HIV risk reduction skills (questionnaire)', 'HIV risk network (questionnaire)']","['six and twelve months after the roll-out of the intervention components', 'six and twelve months after the roll-out of the intervention components', 'six and twelve months after the roll-out of the intervention components', 'six and twelve months after the roll-out of the intervention components']",[],[],[],[],[],[],[],[],[],[],[],['August 2016']
0,104,['NCT01235260'],['REGRANEX-EPI-02'],"['Child', 'Adult', 'Older Adult']",[],['Other Identifier'],[],['The number of becaplermin doses associated with risk of incident cancer and/or cancer death.'],"['From the date of the first becaplermin dispensing beginning October 1, 1999 until the earliest of September 30, 2007, outcome identification, or death.']",[],[],[],[],[],[],[],[],[],[],[],['March 2010']
0,105,['NCT03390660'],[],['Child'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['January 1, 1999']"
0,106,['NCT00837499'],['3P50CA116199-02S1'],"['Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=3P50CA116199-02S1&Fy=all'],['U.S. NIH Grant/Contract'],[],['Expression of a breast tumor phenotype marker (expressed versus not expressed)'],['5 Years'],['University of Texas MD Anderson Cancer Center Website'],['http://www.mdanderson.org'],[],[],[],[],[],[],[],[],[],"['January 1, 2007']"
0,107,['NCT01629537'],[],"['Adult', 'Older Adult']",[],[],"['The PCL is a 17-item self-report measure of the 17 DSM-IV symptoms of PTSD. It is used to screen and diagnose individuals for PTSD, as well as monitoring symptom change during and after treatment. To be compared to the 1 week pre baseline measures at enrollment', 'The PHQ-9 is the nine item depression scale of the Patient Health Questionnaire. The PHQ-9 is a powerful tool for assisting primary care clinicians in diagnosing depression as well as selecting and monitoring treatment. To be compared to the 1 week pre baseline measures at enrollment', ""A 21-question multiple-choice self-report inventory that is used for measuring the severity of an individual's anxiety. To be compared to the 1 week pre baseline measures at enrollment"", 'Assesses disability in work/school activities, family relationships, and social functioning, and it evaluates the functional impact of psychiatric disorders. To be compared to the 1 week pre baseline measures at enrollment', 'To be compared to the 1 week pre baseline measures at enrollment', ""Computer-based assessments of cognitive domains including attention, concentration, reaction time, memory, processing speed, and decision-making. Evaluate changes in an individual's cognitive status over time. To be compared to the 1 week pre baseline measures at enrollment.""]","['PTSD Checklist Military Version (PCL-M)', 'The Patient Health Questionnaire 9 (PHQ-9)', 'Beck Anxiety Inventory (BAI)', 'Sheehan Disability Scale (SDS)', 'Behavioral Reactivity Test (BRT)', 'Automated Neuropsychological Assessment Metric (ANAM)']","['1 week', '1 week', '1 week', '1 week', '1 week', '1 week']",[],[],[],[],[],[],[],[],[],[],[],['June 2011']
0,108,['NCT00351741'],[],"['Adult', 'Older Adult']",[],[],"['days free from nonpulmonary organ failure as adapted from the ARDSnet study in the first 28 days.', 'In-hospital death.', 'Those who develop both clinical and microscopic evidence of pulmonary infection while on the ventilator.', 'Subjects who did not meet predetermined oxygenation and ventilation goals on the study mode despite ventilator- specific optimization were switched to a rescue mode of ventilation.', 'Defined as a new pneumothorax, pneumomediastinum, subcutaneous emphysema, interstitial emphysema, or pneumatocele >2 cm in diameter not associated with a vascular procedure, lung biopsy, or thoracentesis.', 'Defined as carinal or mainstem airway friability and sloughing with associated bleeding. Only diagnosed after the patient had spent at least 7 days on the assigned ventilator mode and had not been diagnosed with inhalation injury on admission']","['Days Free From Nonpulmonary Organ Failure', 'Death', 'Ventilator Associated Pneumonia', 'Need for Rescue Ventilator', 'Barotrauma', 'Ventilator Associated Tracheobronchitis (VATB)']","['28', 'during hospitalization', '28 days', '28 days', '28 days', 'checked daily']",[],[],"['Non-systematic Assessment', 'Non-systematic Assessment']","['defined as a new pneumothorax, pneumomediastinum,subcutaneous emphysema, interstitial emphysema, or pneumatocele >2 cm in diameter not associated with a vascular procedure, lung biopsy, or thoracentesis.', 'VAP as defined by the American Thoracic Society and the Infectious Disease Society of America']","['Respiratory, thoracic and mediastinal disorders', 'Respiratory, thoracic and mediastinal disorders']",[],"['EG000', 'EG001', 'EG000', 'EG001']","['0', '4', '10', '16']","['31', '31', '31', '31']","['0', '4', '10', '16']","['Barotrauma', 'Ventilator Associtated Pneumonia']",['July 2006']
0,109,['NCT01965561'],[],['Adult'],[],[],"['Pain during tourniquet application as measured on a visual analog scale (VAS). The pain scale was a 100-mm-long line on a piece of paper. The subject made a cross mark on the line, which went from the left limit (0 mm) at no pain to the right limit (100 mm) at very severe pain.']",['Pain During Tourniquet Application'],['1 minute'],[],[],[],[],[],[],[],[],[],[],[],['October 2013']
0,110,['NCT01927835'],['11933'],['Adult'],[],['Registry Identifier'],[],"['Magnitude and breadth of HIV-specific binding antibody responses as assessed by multiplex assay', 'HIV-specific CD4+ and CD8+ T-cell response rates', 'Magnitude of HIV-specific CD4+ and CD8+ T-cell responses', 'Humoral and cellular vaccine responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts regimens in South African women compared to South African men', 'Humoral and cellular responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts regimens in South African women', 'Humoral and cellular responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts in South African men', 'Humoral and cellular vaccine responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts regimens in South African adults with low and with high BMI', 'Humoral and cellular responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts in high BMI South African adults', 'Humoral and cellular responses to DNA prime with NYVAC+AIDSVAX B/E boosts and NYVAC prime with NYVAC+AIDSVAX B/E boosts regimens in low BMI South African adults']","['Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', 'Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', 'Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12""]",[],[],[],[],[],[],[],[],[],[],[],[]
0,111,['NCT01704235'],['CPC-12122-L'],"['Adult', 'Older Adult']",[],['Other Identifier'],"[""To understand the extent of preventive care-seeking among Vietnamese American women (foreign and United States-born) and their impact on cervical cancer screening from the perspective and experiences of key informants including primary health care providers. A semi-structured interview guide will be used to assess the extent of preventive care-seeking. The interview guide includes the following topics: thoughts and experiences regarding Vietnamese American women's knowledge and beliefs about how cervical cancer develops, thoughts and experiences regarding Vietnamese American women and use of cancer screening tests such as cervical cancer screening for early detection/preventive health care, thoughts and experiences about Vietnamese American women's lack of familiarity with the term Pap smear or a Pap test, and thoughts and experiences regarding Vietnamese American women's decision and timing to seek medical care and preventive health care.""]",['The extent of preventive care-seeking'],['Duration of the study; Up to 1 year'],[],[],[],[],[],[],[],[],[],[],[],"['November 30, 2012']"
0,112,['NCT01306266'],[],['Adult'],[],[],"['proportions of subjects achieving complete headache relief at 2 hours, sustained headache relief at 24 hours, 24-hour Migraine Quality of Life score, disability 2 hours after dosing, occurrence of associated symptoms, and side effects.']",['24 hour Migraine Quality of Life score'],['24 hours'],[],[],[],[],[],[],[],[],[],[],[],['February 2011']
0,113,['NCT00796315'],[],"['Child', 'Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['December 2008']
0,114,['NCT00005463'],['R01HL046315'],"['Child', 'Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL046315&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['August 1991']
0,115,['NCT03382418'],['12030'],['Adult'],[],['Registry Identifier'],"['Signs/symptoms may include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, maximum severity of systemic symptoms (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Signs/symptoms may include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, maximum severity of systemic symptoms (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Categorized by Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Categorized by MedDRA preferred term, severity, and assessed relationship to study products (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Measured by the binding antibody multiplex assay (BAMA)', 'Measured by the binding antibody multiplex assay (BAMA)', 'Measured by the BAMA', 'Measured by the BAMA', 'Measured by intracellular cytokine staining (ICS)', 'Measured by intracellular cytokine staining (ICS)', 'Measured through laboratory testing', 'Measured through laboratory testing']","['Frequency of severe local reactogenicity signs/symptoms', 'Frequency of severe systemic reactogenicity signs/symptoms', 'Frequency of adverse events (AEs)', 'Frequency of serious adverse events (SAEs) throughout the active surveillance period', 'Response rates of vaccine-induced binding antibodies to HIV proteins', 'Levels of vaccine-induced binding antibodies to HIV proteins', 'Response rates of vaccine-induced binding antibodies to HIV proteins', 'Levels of vaccine-induced binding antibodies to HIV proteins', 'Response rates of CD4+ and CD8+ T cells', 'Levels of CD4+ and CD8+ T cells', 'Response rates of neutralizing antibody responses against HIV-1 isolates', 'Levels of neutralizing antibody responses against HIV-1 isolates']","['Measured through Month 12', 'Measured through Month 12', 'Measured through Month 12', 'Measured through Month 12', 'Measured at Week 2', 'Measured at Week 2', 'Measured at Month 6.5', 'Measured at Month 6.5', 'Measured at Month 6.5', 'Measured at Month 6.5', 'Measured at Month 6.5', 'Measured at Month 6.5']",[],[],[],[],[],[],[],[],[],[],[],"['December 27, 2017']"
0,116,['NCT00054743'],['03-CC-0091'],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['February 6, 2003']"
0,117,['NCT00730964'],[],"['Adult', 'Older Adult']",[],[],"['The frequency of any serious adverse event (SAE) whether it is related to the Optison product or not, after the administration of the Optison product during contrast enhanced echocardiography.']","[""The Frequency of Overall Serious Adverse Events (SAE's) Among Subjects Who Receive Optison (Whether Related to the Product or Not) During Contrast Enhanced Echocardiography in Routine Clinical Practice.""]",['Within 24 hours post contrast administration'],[],[],"['Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment']",[],"['Cardiac disorders', 'Cardiac disorders', 'Vascular disorders', 'Cardiac disorders', 'Cardiac disorders', 'Cardiac disorders']",[],"['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['1', '1', '1', '1', '1', '1']","['1039', '1039', '1039', '1039', '1039', '1039']","['1', '1', '1', '1', '1', '1']","['Non-sustained ventricular tachycardia', 'Left Ventricular thrombus', 'Fluid Overload', 'Coronary Artery Disease', 'Left Ventricular Mass Requiring Surgery', 'Episodes of Sustained Ventricular Tachycardia']",['May 2008']
0,118,['NCT02886689'],[],"['Child', 'Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['January 2007']
0,119,['NCT00005455'],['Z01HL005264'],"['Child', 'Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=Z01HL005264&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['January 1993']
0,120,['NCT01150695'],[],['Adult'],[],[],[],"['Take: proportion of subjects that develop a positive ""take"" response, as assessed by an independent blinded ""take committee,"" following review of photographs taken of the vaccination and placebo sites.', 'Safety: occurrence of solicited systemic AEs.', 'Take: difference in the proportion of subjects that develop a positive ""take"" response between the two vaccine groups as assessed by an independent blinded ""take committee"".', 'Safety: occurrence of solicited local adverse events (AE)s.', 'Immunogenicity: geometric mean titers (GMT) of peak microagglutination titer for each arm of the study. For each subject, the peak titer is defined by the maximum titer among all the available measures.', 'Take: difference in the proportion of subjects that develop a positive ""take"" response between the two vaccine groups as assessed by the clinical site.']","['Study Visit 5 (7-9 days post vaccination).', 'Within 28 days post vaccination.', 'Study Visit 5 (7-9 days post vaccination).', 'Within 28 days post vaccination.', 'Visits 6, 7 and 8 post vaccination (Day 14, Day 28 and Day 56)..', 'Study Visit 5 (7-9 days post vaccination).']",[],[],[],[],[],[],[],[],[],[],[],['September 2010']
0,121,['NCT00245076'],['TCRB-OHSR-2765'],"['Adult', 'Older Adult']",[],[],[],"['Visits to the website after registration at 1, 3, and 6 months', 'Satisfaction with the website at 1, 3, and 6 months']",[],[],[],[],[],[],[],[],[],[],[],[],['April 2005']
0,122,['NCT00935623'],['HSRRB A-15209'],['Adult'],[],['Other Identifier'],[],"['Parasitologic and clinical infections in challenge volunteers will be characterized by descriptive analysis of prepatent and patent periods, incubation period and time to resolution of signs and symptoms, and timing and number of relapses.']",['Cross-sectional'],[],[],[],[],[],[],[],[],[],[],[],"['April 21, 2009']"
0,123,['NCT03688126'],[],"['Adult', 'Older Adult']",[],[],"['This will be a composite score from PmNTB subtests Free and Cued Selective Reminding Test, Story Recall, Visual Paired Associates; and experimental measures: Cogstate One-Card Learning, Face Name Associative Memory Exam, and Behavioral Pattern Separation of Objects, calculated in a manner parallel to how the primary composite outcome is calculated. This secondary outcome is the slope of these composite scores over time (standard deviation units per year) with less negative (or positive) slopes reflecting better performance.', 'This will be a composite score from PmNTB subtests Number Span, Word Fluency, Trail-Making Test Part B, Digit Symbol Substitution Test; and experimental measures: Cogstate One Back, and Digital Clock Drawing Test, calculated in a manner parallel to the primary composite outcome is calculated. This secondary outcome is the slope of these composite scores over time (standard deviation units per year) with less negative (or positive) slopes reflecting better performance.', 'This will be a composite score from PmNTB subtests Trail-Making Test Part A and Digit Symbol Substitution Test; and experimental measures: Cogstate Detection and Identification, and Digital Clock Drawing Test calculated in a manner parallel to the primary composite outcome is calculated. This secondary outcome is the slope of these composite scores over time (standard deviation units per year) with less negative (or positive) slopes reflecting better performance.', 'The Clinical Dementia Rating (CDR) is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively) across six domains. Scores from these domains are summed ranging from 0 to 18, with higher scores reflecting worse performance. The secondary outcome will be the change in the mean scores from baseline to 2 years.', ""The Lawton-Brody IADL is a commonly used scale in clinical practice and research that assess a person's functional ability to complete tasks such as shopping, food preparation, transportation, and managing finances. Scores range from 0 to 8 for women and from 0 to 5 for men, with higher scores reflecting better performance. The secondary outcome will be the change in the mean scores from baseline to 2 years."", 'The ECog is a validated scale developed to assess everyday functional status. The short form of the instrument will be used in U.S. POINTER. Scores range from 0 to 4 with higher scores reflecting greater poorer function. The secondary outcome will be the change in the mean scores from baseline to 2 years.', 'DCTClock assesses cognition via novel software that processes information from a commercially available digital pen. This software is able to capture nuances in cognitive performance. Many metrics can be generated with this device. The secondary outcome for U.S. POINTER will be time (in seconds) to completion of the clock drawing test, with longer times reflecting poorer processing speed. The secondary outcome will be the change in the mean scores from baseline to 2 years.', 'This composite score is based on self-reported Physical Activity Questionnaire, Rush Food Frequency Questionnaire, and the Cognitive Activity Questionnaire. Participants will be ordered with respect to each index, with higher scores reflecting 1) greater daily physical activity, 2) greater conformance with the MIND Diet, and 3) greater cognitive activity. Based on these orderings, participants will be assigned percentiles with respect to each measure relative to the overall group. These percentiles will range from 0 to 100. The secondary outcome will be the average of the three percentiles. The secondary outcome will be the change in the mean scores from baseline to 2 years.']","['Episodic Memory', 'Executive Function', 'Processing Speed', 'Clinical Dementia Rating-Sum of Boxes', 'Instrumental Activities of Daily Living (IADL)', 'Everyday Cognition (ECog)', 'Digital Clock Drawing Test (DCTClock)', 'Lifestyle Composite']","['up to 2 years', 'up to 2 years', 'up to 2 years', 'up to 2 years', 'up to 2 years', 'up to 2 years', 'up to 2 years', 'up to 2 years']",[],[],[],[],[],[],[],[],[],[],[],"['January 8, 2019']"
0,124,['NCT02053506'],[],['Adult'],[],[],['Fluid is sampled from blister wound area at various time-points and analyzed for concentration of pro-inflammatory cytokines.'],['Suction blister cytokine response'],"['4, 7 and 24 hours']",[],[],[],[],[],[],[],[],[],[],[],['January 2014']
0,125,['NCT03933215'],[],"['Adult', 'Older Adult']",[],[],"['For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.', 'For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with hospitalization, diagnosis or reason for hospitalization will be reported.', 'For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with glucocorticoid use up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.', 'For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months prior to baseline (retrospectively collected data) will be reported.', ""A serious adverse event (SAE) is an adverse event (AE) that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or is otherwise considered medically important. An ADR is a response to a medicinal product which is noxious and unintended. An AESI is an AE of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor can be appropriate.""]","['Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Total Score at Month 6, 12 and 24', 'Change From Baseline in 36-Item Short Form Health Survey (SF-36) Total Score at Month 6, 12 and 24', 'Change From Baseline in Modified Fatigue Impact Scale - 5-item version (MFIS-5) Total Score at Month 6, 12 and 24', 'Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24', 'Change From Baseline in 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Total Score at Month 6, 12 and 24', 'Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24', 'Number of Participants With Adherence to Treatment as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)', 'Percentage of Participants with Relapse (Prospective Assessment)', 'Percentage of Participants With Relapse Associated With Hospitalization, Diagnosis or Reason for Hospitalization', 'Percentage of Participants With Relapse Associated With Glucocorticoid Use', 'Treatment Pattern as Evaluated by Number of Participants With Previous Treatment for Multiple Sclerosis (MS)', 'Percentage of Participants Who Discontinue Cladribine Tablets', 'Percentage of Participants With Reason for Discontinuation of Cladribine Tablets', 'Elapsed Time to Discontinuation After First Dose of Cladribine Tablets', 'Number of Doses Received by Participants as per United States Prescribing Information', 'Percentage of Planned Doses Received by Participants as per United States Prescribing Information', 'Number of Participants with Subsequent Treatment Chosen Following Discontinuation of Cladribine Tablets', 'Number of Participants Assessed of Concomitant Multiple Sclerosis Medications Used During Study Period', 'Annualized Relapse Rate (ARR) (Retrospective Assessment)', 'Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs) and Special Situations']","['Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0) and at the end of Months 1, 2, 13 and 14', 'Month 12 and 24', 'Month 12 and 24', 'Month 12 and 24', 'At Baseline (Month 0)', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Up to 24 Months prior Baseline (Month 0)', 'Baseline (Month 0) up to 24 months']","['Trial Awareness and Transparency website', 'US Medical Information website, Medical Resources']","['https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0078', 'https://medical.emdserono.com/en_US/home.html']",[],[],[],[],[],[],[],[],[],"['May 21, 2019']"
0,126,['NCT03933202'],[],"['Adult', 'Older Adult']",[],[],"['A relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.', 'A relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with hospitalization, diagnosis or reason for hospitalization will be reported.', 'A relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with glucocorticoid use up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.', 'A relapse will be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months prior to baseline (retrospectively collected data) will be reported.', ""A serious adverse event (SAE) is an adverse event (AE) that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or is otherwise considered medically important. An ADR is a response to a medicinal product which is noxious and unintended. An AESI is an AE of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor can be appropriate.""]","['Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Total Score at Month 6, 12 and 24', 'Change From Baseline in 36-Item Short Form Health Survey (SF-36) Total Score at Month 6, 12 and 24', 'Change From Baseline in Modified Fatigue Impact Scale - 5-item version (MFIS-5) Total Score at Month 6, 12 and 24', 'Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24', 'Change From Baseline in 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Total Score at Month 6, 12 and 24', 'Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24', 'Number of Participants With Adherence to Treatment as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)', 'Percentage of Participants with Relapse (Prospective Assessment)', 'Percentage of Participants With Relapse Associated With Hospitalization, Diagnosis or Reason for Hospitalization', 'Percentage of Participants With Relapse Associated With Glucocorticoid Use', 'Treatment Pattern as Evaluated by Number of Participants With Previous Treatment for Multiple Sclerosis (MS)', 'Percentage of Participants Who Discontinue Cladribine Tablets', 'Percentage of Participants With Reason for Discontinuation of Cladribine Tablets', 'Elapsed Time to Discontinuation After First Dose of Cladribine Tablets', 'Number of Doses Received by Participants as per United States Prescribing Information', 'Percentage of Planned Doses Received by Participants as per United States Prescribing Information', 'Number of Participants with Subsequent Treatment Chosen Following Discontinuation of Cladribine Tablets', 'Number of Participants Assessed of Concomitant Multiple Sclerosis Medications Used During Study Period', 'Annualized Relapse Rate (ARR) (Retrospective Assessment)', 'Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs) and Special Situations']","['Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0), Month 6, 12 and 24', 'Baseline (Month 0) and at the end of Months 1, 2, 13 and 14', 'Month 12 and 24', 'Month 12 and 24', 'Month 12 and 24', 'At Baseline (Month 0)', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Baseline (Month 0) up to 24 Months', 'Up to 24 Months prior Baseline (Month 0)', 'Baseline (Month 0) up to 24 months']","['Trial Awareness and Transparency website', 'US Medical Information website, Medical Resources']","['https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0079', 'https://medical.emdserono.com/en_US/home.html']",[],[],[],[],[],[],[],[],[],"['July 22, 2019']"
0,127,['NCT00005171'],['R01HL033407'],"['Child', 'Adult', 'Older Adult']",['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL033407&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['December 1984']
0,128,['NCT01256164'],[],"['Adult', 'Older Adult']",[],[],['Number of participants with Adverse events and clinically-significant changes/findings on labs and physical examination as well as incidence of re-operation for bleeding at the TBS'],"['Safety', 'Number of Subjects Achieving Hemostasis at 3 Minutes', 'Number of Participants Achieving Hemostasis at 5 Minutes', 'Number of Patients Achieving Hemostasis at 10 Minutes']","['28 Days', '3 minutes', '5 minutes', '10 minutes']",[],[],[],[],"['Blood and lymphatic system disorders', 'Infections and infestations', 'Respiratory, thoracic and mediastinal disorders', 'Infections and infestations', 'Injury, poisoning and procedural complications', 'Vascular disorders', 'Injury, poisoning and procedural complications', 'Vascular disorders', 'Injury, poisoning and procedural complications', 'Gastrointestinal disorders', 'Gastrointestinal disorders', 'Injury, poisoning and procedural complications']",[],"['EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001']","['2', '0', '1', '0', '1', '0', '1', '0', '0', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '0', '1']","['47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23', '47', '23']","['2', '0', '1', '0', '1', '0', '1', '0', '0', '1', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '1', '0', '0', '1']","['Anemia', 'Cellulitis', 'Pulmonary emobolism', 'Herpes zoster', 'Arteriovenous fistula thrombosis', 'Hypotension', 'Pancreatic leak', 'Deep cenous thrombosis', 'Post procedural bile leak', 'Small bowel obstruction', 'Gastrointestinal bleeding', 'Scrotal hematoma']",['December 2010']
0,129,['NCT03631472'],[],"['Adult', 'Older Adult']",[],[],"[""The change from baseline at 6 months in St. George's Respiratory Questionnaire (SGRQ)"", ""The change from baseline at 12 months in St. George's Respiratory Questionnaire (SGRQ)"", 'The change from baseline at 6 months in COPD Assessment Test (CAT)', 'The change from baseline at 12 months in COPD Assessment Test (CAT)']","['Clinical Utility - SGRQ at 6 months', 'Clinical Utility - SGRQ as 12 months', 'Clinical Utility - CAT at 6 months', 'Clinical Utility - CAT at 12 months']","['6 months', '12 months', '6 months', '12 months']",[],[],[],[],[],[],[],[],[],[],[],"['July 6, 2018']"
0,130,['NCT03699709'],['R01MD011596'],['Adult'],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01MD011596&Fy=all'],['U.S. NIH Grant/Contract'],"['Change in food budgeting skills will be estimated using the Food Resource Management Scale. The scale includes 4 questions related to shopping behaviors to maximize food resources. The Food Resource Management Scale is a Likert-type scale with responses ranging from 1 (never) to 5 (always). Responses to the four questions will be averaged to create a total Food Resource Management Score. Change from baseline with be assessed at 6 months and 12 months (12 months - baseline; 6 months - baseline). As the intervention hopes to increase food budgeting skills, higher after-before differences represent a better outcome.', 'Change in cooking skills will be estimated using a minor modification of the Cooking Confidence Scale. The Cooking Confidence Scale includes 6 questions related to confidence in preparing healthy foods. It is a Likert-type scale with responses ranging from 1 (not at all confident) to 5 (very confident). Responses to the questions will be averaged. Change from baseline with be assessed at 6 months and 12 months (12 months - baseline; 6 months - baseline). As the intervention hopes to increase cooking skills, higher after - before differences represent a better outcome.', 'The proportion of those approached that participate in intervention (and the number who subsequently participate) will be used as a marker of intervention reach.', 'The investigators will assess adherence to the study protocol and document barriers and facilitators to implementation throughout the trial.', ""During months 6 and 12, a sub-sample of study participants in the intervention arm will meet with study staff by phone for semi-structured interviews to evaluate the overall intervention. Qualitative analyses will assess participant's satisfaction with the intervention."", 'Dose will be assessed in the intervention arm only', 'Dose will be assessed in the intervention arm only']","['change (from baseline) in food budgeting skills (measured using the Food Resource Management Scale) at 6 months and 12 months', 'change (from baseline) in cooking skills (measured using the Cooking Confidence Scale) at 6 months and 12 months', 'Process evaluation: intervention reach', 'Process evaluation: intervention fidelity', 'Process evaluation: intervention satisfaction (among those in the intervention arm)', 'Process evaluation: intervention dose delivered (i.e., number of lessons included in the curriculum available for participants)', 'Process evaluation: intervention dose received (i.e., number of lessons included in the curriculum completed by participants)']","['measured at baseline, and months 6 and 12', 'measured at baseline, and months 6 and 12', 'through study completion, estimated 12 months to complete intervention per participant', 'through study completion, estimated 12 months to complete intervention per participant', 'Semi-structured interviews will be done at months 6 and 12.', 'through study completion, estimated 12 months to complete intervention per participant', 'through study completion, estimated 12 months to complete intervention per participant']",[],[],[],[],[],[],[],[],[],[],[],"['February 27, 2020']"
0,131,['NCT00237263'],[],"['Adult', 'Older Adult']",[],[],[],"['On time based on patient diary (up to 104 weeks)', 'UPDRS score at every 16 weeks']",[],['Results fro CCOM998A1204 from the Novartis Clinical Trials website.'],['https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2541'],[],[],[],[],[],[],[],[],[],['February 2003']
0,132,['NCT02939131'],"['UM1AI068632', 'UM1AI068616', 'UM1AI106716']","['Child', 'Adult']","['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=UM1AI068632&Fy=all', 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=UM1AI068616&Fy=all', 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=UM1AI106716&Fy=all']","['U.S. NIH Grant/Contract', 'U.S. NIH Grant/Contract', 'U.S. NIH Grant/Contract']","['Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.', 'Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Very poor .... 6=Excellent', 'Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Never ... 6=Always', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report for those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report tor those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.1=Very poor .... 6=Excellent', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report for those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Never .... 6=Always', 'We will compute the number of scheduled counseling sessions attended. This number focuses on visits scheduled at study weeks 1, 6, 12, and 24. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will compute the number of scheduled medication management sessions (COMB-R only) attended. This includes visits scheduled at planned study visits (weeks 1, 6, 12 and 24). Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will compute the # study visits completed as the number of scheduled study visits completed. Visits were scheduled at study weeks 0, 1, 6, 12, 24, 36 and 48. However in some cases, weeks 0 and 1 visits were done on the same day.', 'Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) Score over 48 Weeks. This scale goes from 0 to 27 with a lower score indicating less symptomatology. .Scores for participants at each site are averaged and the averages are analyzed.', 'The percentage of participants with a decrease in Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) score of more than 50% from week 0 to week X will be computed at each site and those percentages will be analyzed. Refer to above definition.', 'A remission is a Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) score <= 5. The percentage of participants at each site with remission will be computed and those percentages will be analyzed.', 'QIDS-SR score: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), Center for Disease Control and Prevention (CDC) clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age (from Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Response to Treatment: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), CDC clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was done based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age. (from the Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Remission: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), CDC clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was done based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age. (from the Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Measured as follows: Ever used; past three months use frequency; # drinks per day; any binge drinking.', 'Measured as follows: Ever used; past three months use frequency', 'Measured as follows: Ever used; past three months use frequency for cannabis, cocaine, amphetamine, inhalants, sedatives, hallucinogens, opioids', 'Assessed as: condom use (importance, confidence, frequency), sex as exchange commodity, number of sex partners', 'We will count the total numbers of COMB-R and ESC counseling sessions administered over the intervention period, including both interim and scheduled visits. The average number of sessions will be computed for each site and those averages will be analyzed. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'For COMB-R; Here, we will assess the types of cognitive behavioral therapy (CBT) items covered in the COMB-R group over the intervention period. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'Here we will summarize the types of counseling approaches used by the ESC clinicians over the intervention period. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'For COMB-R, we will compute the number of CBT Medication Management (MM) sessions attended over 24 weeks . We will also assess the stages of the MM algorithm in the COMB-R group. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will assess whether or not participants were taking psychiatric medications at entry and at week 24 and compute the percent of participants at each site taking medications. We also will compute the percent of study time during which participants were taking psychiatric medications overall and by classes of psychiatric medications.from study entry through week 24. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will develop an algorithm to count the number of interim visits with both counseling clinician and prescribing clinician, defined as those outside of the scheduled study visits. Site mean numbers will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'Client satisfaction will be the mean of the 8 questionnaire items. Each is rated on a likert scale from 1-4, with 4 being the best acceptability. Site mean scores will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', '5 items were rated on a Likert scale from 0-3 with one additional overall question. The mean of the 5 items and the single overall item will be compared between groups. Site mean scores will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'The COMB-R MM acceptability scale included 3 items scored on a Likert scale from 0-4 and one overall question. The ESC acceptability scale included 2 items (similar to Questions 1 and 3 on the MM scale). The 3 COMB-R MM items will be averaged (mean) and the two items on the ESC scale will be averaged (mean) and these scores will be compared. The single overall score will be reported for the COMB-R MM clinicians. Site mean scores will be compared across treatments.\n\nAnalysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'In this analysis only ""new"" events are counted; as identified by MedDRA Preferred Term; that is, those which were first reported after study entry. The percent of participants at each site with each a grade 3 or higher adverse event, categorized as 1) a sign/symptom or 2) diagnosis and 3) participants with at least one ""trigger"" event (psychiatric hospitalization or suicide attempt) are computed. The average of these site-level percentages within each treatment arm will be compared. Note, in some cases due to sparseness (few events reported at sites within a treatment group), the lower bound of the 95% confidence interval was less than zero . In those cases, the bounds were truncated to zero.', 'In this analysis only ""new"" events are counted; as identified by MedDRA Preferred Term; that is, those which were first reported after study entry. The percent of participants at each site with each a grade 3 or higher adverse event, categorized as 1) a sign/symptom or 2) diagnosis and 3) participants with at least one ""trigger"" event (psychiatric hospitalization or suicide attempt) the mean of these percents will be compared across groups']","['Adherence Outcomes: Adherence to Anti-HIV Medications - Number of Days in Last 30 With Any Missed Doses', 'Adherence Outcomes: Adherence to Anti-HIV Medications - How Good Participant Was at Taking Medicines as Instructed', 'Adherence Outcomes: Adherence to Anti-HIV Medications - How Often Did Participant Take Medications as Instructed', 'Adherence Outcomes: Adherence to Psychiatric Medications - Number of Days in Last 30 With Any Missed Doses', 'Adherence Outcomes: Adherence to Psychiatric Medications - How Good Participant Was at Taking Medications as Instructed', 'Adherence Outcomes: Adherence to Psychiatric Medications - How Often Did Participant Take Medicines as Instructed', 'Adherence Outcomes: Adherence to Psychotherapy Sessions', 'Adherence Outcomes: Adherence to COMB-R Medication Management Sessions', 'Adherence Outcomes: Adherence to Study Visits', 'Depression Outcomes: QIDS-SR Score Over 48 Weeks.', 'Depression Outcomes: QIDS-SR Response to Treatment Over 48 Weeks', 'Depression Outcomes: QIDS-SR Score Remission Over 48 Weeks', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: QIDS-SR Score (Defined Above)', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Response to Treatment (Defined Above)', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Remission (Defined Above)', 'Behavioral Risk Outcomes: Alcohol Use', 'Behavioral Risk Outcomes: Tobacco Use', 'Behavioral Risk Outcomes: Drug Use', 'Behavioral Risk Outcomes: Sex-Risk Behaviors', 'To Describe the Implementation Fidelity at COMB-R Sites and the Counseling Strategies and Medication Patterns at ESC Sites: The Total Numbers of Counseling Sessions', 'Implementation Fidelity (COMB-R Sites); Counseling Strategies (ESC Sites) - Types of Counseling Approaches COMB-R Sites', 'Implementation Fidelity (COMB-R Sites); Counseling Strategies (ESC Sites) - Types of Counseling Approaches ESC Sites', 'Implementation Fidelity (COMB-R Sites); Medication Management', 'Acceptability: Frequency of Psychiatric Medication Use', 'Acceptability: Number of Interim Visits', 'COMB-R and ESC Acceptability Among Participants', 'COMB-R and ESC Acceptability Among Counseling Clinicians', 'COMB-R MM and ESC Acceptability Among Prescribing Clinicians', 'Grade 3 or Higher Adverse Events (AE), Psychological Hospitalizations, and Suicide Attempts', 'Grade 3 or Higher Adverse Events (AE), Psychological Hospitalizations, and Suicide Attempts']","['Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 weeks', 'Over 24 weeks', 'Over 24 and 48 Weeks', 'Over 48 Weeks', 'Week 48', 'Week 48', 'Over 48 Weeks', 'Over 48 Weeks', 'Over 48 Weeks', 'Weeks 24 and 48', 'Weeks 24 and 48', 'Weeks 24 and 48', 'Weeks 24 and 48', 'over 24 weeks', 'over 24 Weeks', 'Over 24 weeks', '24 Weeks', '24 weeks', '24 Weeks', '24 Weeks', '24 Weeks', '24 Weeks', 'Over 24 Weeks', 'Over 48 weeks']","['The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (AE) (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017, will be used to grade the severity of most adverse events in this study.']",['http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables'],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Hepatobiliary disorders', 'Infections and infestations', 'Infections and infestations', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders', 'Psychiatric disorders']","['MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0', 'MedDRA 23.0']","['EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001', 'EG000', 'EG001']","['1', '0', '0', '1', '0', '1', '0', '1', '1', '0', '1', '0', '0', '1', '3', '2']","['81', '75', '81', '75', '81', '75', '81', '75', '81', '75', '81', '75', '81', '75', '81', '75']",[],"['Cholecystitis acute', 'Appendicitis', 'Pneumonia', 'Depression', 'Major depression', 'Mental disorder', 'Substance-induced psychotic disorder', 'Suicide attempt']","['March 6, 2017']"
0,133,['NCT03488264'],[],"['Adult', 'Older Adult']",[],[],"['Quality of life will be measured using Adult Sickle Cell Quality of life Measures (ASCQ-Me) subscales for emotional impact, pain episodes, pain impact, sleep impact, social functioning impact, and stiffness impact. For pain episodes separate composite scores are calculated for pain frequency (0-11) and severity (0-22). Higher scores indicate worse health status. Raw scores for the remaining scales range 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'Score on the ASCQ-Me Emotional Impact - Raw scores for this scale ranges 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'Score on ASCQ-Me Pain episodes - For pain episodes separate composite scores are calculated for pain frequency (0-11) and severity (0-22). Higher scores indicate worse health status.', 'Score on ASCQ-Me Pain impact - Raw scores for this scale ranges 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'Score on ASCQ-Me Sleep impact - Raw scores for this scale ranges 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'Score on ASCQ-Me Social functioning impact - Raw scores for this scale ranges 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'Score on the ASCQ-Me stiffness impact - Raw scores for this scale ranges 5-25 and are developed by using T-Score transformation to standardize raw scores to have a mean of 50 (indicates an average health score on the scale) and standard deviation of 10 (represents one SD). Higher scores indicate healthier status.', 'The ASCQ-Me Medical History Checklist (SCD-MHC) contains 9 items that list treatments and conditions associated with SCD (leg ulcers, avascular necrosis) that are scored dichotomously (0-9) with higher scores indicating higher disease severity.']","['Quality of life', 'Emotional impact', 'Pain episodes', 'Pain impact', 'Sleep impact', 'Social functioning impact', 'Stiffness impact', 'Disease Severity']","['14-21 minutes', '2-3 minutes', '2-3 minutes', '2-3 minutes', '2-3 minutes', '2-3 minutes', '2-3 minutes', '2-3 minutes']",[],[],[],[],[],[],[],[],[],[],[],"['February 13, 2018']"
0,134,['NCT01873482'],[],"['Adult', 'Older Adult']",[],[],[],['written narrative of experience'],['During the first hour after the intervention'],[],[],[],[],[],[],[],[],[],[],[],['May 2014']
0,135,['NCT02829073'],[],['Adult'],[],[],"['Change in TRQ score at 2 and 4 months compared to baseline', 'Change of tinnitus awareness at 2, 4, and 6 months compared to baseline', 'Change of bothersome tinnitus at 2, 4, and 6 months compared to baseline', 'Change in PLC-M score at 2, 4, and 6 months compared to baseline', 'Change in HADS score at 6 months compared to baseline', 'Change in MML at 6 months compared to baseline', 'Change in LDL at 6 months compared to baseline']","['Tinnitus Reaction Questionnaire (TRQ) Midterm', 'Tinnitus Reaction Questionnaire (TRQ) Awareness', 'Tinnitus Reaction Questionnaire (TRQ) Bothersome', 'PTSD Checklist-Military (PCL-M)', 'Hospital Anxiety and Depression Scale (HADS)', 'Minimum Masking Level (MML) (an audiometric test)', 'Loudness Discomfort Levels (LDL) (an audiometric test)']","['Baseline and two, four, and six months after enrollment', 'Baseline and two, four, and six months after enrollment', 'Initial and two, four, and six months after enrollment', 'Baseline and two, four, and six months after enrollment', 'Baseline and six months after enrollment', 'Baseline and six months after enrollment', 'Baseline and six months after enrollment']",[],[],[],[],[],[],[],[],[],[],[],['April 2016']
0,136,['NCT01369030'],[],"['Adult', 'Older Adult']",[],[],"['Mean satisfaction with medication was rated on 1 to 9 point scale, 1 indicating ""not at all satisfied"" and 9 as ""very satisfied.""']","['Proportion of Patients Reporting Difficulty in Daily Functioning Due to Depressive Symptoms', 'Change in Overall Patient Satisfaction With Deplin® Using a 9-point Satisfaction Scale']","['Baseline to Endpoint (90 days)', 'Baseline to Endpoint (90 days)']",[],[],[],[],[],[],[],[],[],[],[],['November 2010']
0,137,['NCT01568424'],[],"['Child', 'Adult', 'Older Adult']",[],[],"['CVP is a measure of right heart filling pressure, or the preload to the right ventricle. During RVAD support, the CVP decreases as blood is drawn into the pump and then ejected into the pulmonary artery.', 'MAP is the mean value for the blood pressure in the arterial circulation. During RVAD support, this value provides information regarding the adequacy of cardiac output from the left ventricle.', 'Cardiac output (L/min) divided by the body surface area (m2)', 'BUN is a measure of renal function', 'Creatinine is a measure of renal function', 'Total bilirubin is a measure of hepatic function']","['Central Venous Pressure (CVP)', 'Mean Arterial Pressure (MAP)', 'Cardiac Index (CI)', 'Blood Urea Nitrogen (BUN)', 'Creatinine', 'Total Bilirubin']","['Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal.', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal.', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal']",[],[],"['Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment', 'Systematic Assessment']",[],"['Infections and infestations', 'Blood and lymphatic system disorders', 'Respiratory, thoracic and mediastinal disorders', 'Cardiac disorders', 'Cardiac disorders', 'Hepatobiliary disorders', 'Renal and urinary disorders', 'Nervous system disorders', 'Vascular disorders', 'Cardiac disorders', 'Cardiac disorders', 'Blood and lymphatic system disorders', 'Product Issues', 'Cardiac disorders', 'Psychiatric disorders', 'Vascular disorders', 'General disorders']",[],"['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['13', '16', '16', '13', '5', '0', '11', '4', '1', '4', '6', '2', '0', '1', '1', '1', '7']","['25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25', '25']","['23', '40', '19', '14', '9', '0', '11', '4', '1', '5', '7', '2', '0', '1', '1', '1', '17']","['Infection', 'Bleeding', 'Respiratory Failure', 'Arrhythmias', 'Hypertension', 'Hepatic Dysfunction', 'Renal Failure', 'Neurologic Dysfunction (Stroke)', 'Thrombotic Vascular', 'Pericardial Fluid Collection', 'Right Heart Failure', 'Hemolysis', 'Device Failure', 'Myocardial Infarction', 'Psychiatric Episode', 'Arterial non-CNS', 'Other']",['September 2009']
0,138,['NCT02406599'],[],"['Adult', 'Older Adult']",[],[],"['Proportion of patients with Positive Margin presence on the Outermost Shaving after the initial lumpectomy surgery', 'Objective evaluation by an evaluator blinded to arm assignment', 'Proportion of patients who underwent a repeat lumpectomy procedure', 'Proportion of patients who underwent a repeat lumpectomy procedure or a mastectomy', 'Proportion of patients from whom shavings were taken']","['Positive Margin presence on the Outermost Shaving after the initial lumpectomy surgery', 'Cosmesis evaluation', 'Repeat lumpectomy rate', 'Repeat lumpectomy and mastectomy rate', 'Diagnostic Accuracy at the Patient Level (ignoring location)']","['Participants will be followed only for the initial lumpectomy duration. information will be available 2-3 weeks (avarage) from initial lumpectomy date', 'participants will be followed until 6 months ± 1 month after last surgical treatment visit, an avarage of of 8 months following initial lumpectomy', 'Participants will be followed for 2-5 weeks (average)', 'Participants will be followed for 2-5 weeks (average)', 'Participants will be followed only for the initial lumpectomy duration. information will be available 2-3 weeks (avarage) from initial lumpectomy date']","['A randomized prospective study of lumpectomy margin assessment with use of MarginProbe in patients with nonpalpable breast malignancies.', 'Dune Medical Devices official website']","['http://www.ncbi.nlm.nih.gov/pubmed/24595800', 'http://www.dunemedical.com']",[],[],[],[],[],[],[],[],[],['June 2015']
0,139,['NCT03965195'],[],"['Adult', 'Older Adult']",[],[],"['To determine the differences in each pneumonia and influenza-related hospitalization rates during the 2019-20 and 2020-21 influenza seasons experienced by long-stay nursing home residents in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older.', 'To determine the differences in each pneumonia-related hospitalization rates during the 2019-20 and 2020-21 influenza seasons experienced by long-stay nursing home residents in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older.', 'To determine the differences in each major adverse cardiovascular event-related (MACE) hospitalization rates during the 2019-20 and 2020-21 influenza seasons experienced by long-stay nursing home residents in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older.', ""To determine the differences in long-stay residents' cardiorespiratory-related hospitalization rates each season and across two seasons in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older."", ""To determine the differences in long-stay residents' ICU stay each season and across two seasons in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older."", ""To determine the differences in long-stay residents' mortality rates each influenza season and both seasons in facilities randomized to either RIV4 or IV4 for each, residents 18 years of age and older and those 65 years of age and older."", ""To determine the differences in long-stay residents' composite Activities of Daily Living (ADL) function score based on the MDS experienced during the influenza season by selected comorbidities and specific to respiratory illness, in facilities randomized to either RIV4 or IV4 combined over two seasons for each, residents 18 years of age and older and those 65 years of age and older."", 'To determine differences in facility-reported outbreaks each season and across two seasons in facilities randomized to either RIV4 or IV4', ""To determine differences in long-stay residents' all-cause hospitalization rates as an interim exploratory analysis based on the Minimum Data Set 3.0 for each, residents 18 years of age and older and those 65 years of age and older.""]","['Differences in each pneumonia and influenza-related hospitalization rates', 'Differences in pneumonia-related hospitalization rates', 'Differences in major adverse cardiovascular event-related (MACE) hospitalization rates', 'Differences in cardiorespiratory-related hospitalization rates', 'Differences in ICU stay', 'Differences in mortality rates', 'Differences in activities of daily living (ADL) function score', 'Differences in facility-reported outbreaks', 'Differences in all-cause hospitalization rates']","['Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season', 'Up to 8 months each influenza season']",[],[],[],[],[],[],[],[],[],[],[],"['July 20, 2019']"
0,140,['NCT01368549'],[],"['Adult', 'Older Adult']",[],[],[],"[""To determine if Metanx® affects a subject's pain level using a 10-point Visual Analog Scale (VAS)"", 'To determine if Metanx® affects a subject\'s ""quality of life"" as determined by a symptom impact module.', 'To determine overall patient satisfaction with Metanx® using a 10-point satisfaction scale']","['Baseline, Week 6 and Week 12', 'Baseline, Week 6 and Week 12', 'Baseline, Week 6 and Week 12']",[],[],[],[],[],[],[],[],[],[],[],['January 2011']
0,141,['NCT01370954'],[],"['Adult', 'Older Adult']",[],[],[],['To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale'],['Weeks 6 and 12'],[],[],[],[],[],[],[],[],[],[],[],['May 2011']
0,142,['NCT01339546'],['B1851041'],"['Child', 'Adult', 'Older Adult']",[],['Other Identifier'],[],"['Change in ambulatory care visit rates for acute otitis media between: 1) 1997-99 to 2001-09; and 2) between 1997-99 to 2011-13 among children less than 5 years old. (Timeframes are retrospective)', 'Change in ambulatory care visit rates for myringotomy tube insertion between: 1) 1997-99 to 2001-09; and 2) between 1997-99 to 2011-13 among children less than 5 years old. (Timeframes are retrospective', 'Change in ambulatory care visit rates for rash between 2001-09 to 2011 -13 among children less than 5 years old. (Timeframes are retrospective)', 'Change in ambulatory care visit rates for trauma between 2001-09 to 2011-13 among children less than 5 years old. (Timeframes are retrospective)']","['1) 1997-99 inclusive (3 yrs); 2) 2001-09 inclusive (9 yrs) and 3) 2011-13 inclusive (3 yrs)', '1) 1997-99 inclusive (3 yrs); 2) 2001-09 inclusive (9 yrs) and 3) 2011-13 inclusive (3 yrs)', '1) 2001-09 inclusive (9 yrs) and 2) 2011-13 inclusive (3 yrs)', '1) 2001-09 inclusive (9 yrs) and 2) 2011-13 inclusive (3 yrs)']","['To obtain contact information for a study center near you, click here.']",['https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6096A1-4018&StudyName=National%20Trends%20in%20Otitis%20Media%20in%20Children%20Under%205%20Years%20of%20Age%20'],[],[],[],[],[],[],[],[],[],"['June 9, 2010']"
0,143,['NCT02252159'],[],"['Adult', 'Older Adult']",[],[],"['The MPN-SAF TSS is a validated 10-item instrument that efficiently assesses the prevalence and severity of PV symptoms in both clinical practice and trial settings. Higher scores indicate more severe symptoms and greater inactivity with a possible total score range of 0-100.', 'WPAI-SHP is a validated 6-item instrument that measures the effect of overall health and specific symptoms on productivity at work and outside of it. All outcomes are presented as a proportion, with 0% representing minimal/no impairment and 100% representing maximal impairment or productivity loss.', 'The amount of health care received by a paid healthcare worker or by an unpaid caregiver', 'A patients self-reported assessment of burden including pain at site, difficulty and inconvenience of scheduling and cost factors.']","['Incidence (frequency) of adverse events (for those patients on active therapies, including PHL)', 'Patient-reported outcomes as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms', 'Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) score for assessment of work productivity and activity impairment', 'European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) for Health Related Quality of Life (HRQoL)', 'Caregiver burden', 'Burden of phlebotomy (PHL)']","['Baseline through end of study. Approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months']",['Related Info'],['http://www.RevealPVStudy.com'],[],[],[],[],[],[],[],[],[],['July 2014']
0,144,['NCT04072289'],[],"['Adult', 'Older Adult']",[],[],"['95% of eyes <1.00D of MRSE change at latter of 2 postop refractions', 'mean rate of change of MRSE <0.5D/year (0.04D/mo)', 'mean rate of change of MRSE decreases monotonically over time', '95% CI for the mean rate of change includes zero', 'incidence of best spectacled correction worse than 20/40', 'incidence of loss of >2 lines of best spectacled corrected visual acuity', 'incidence of induced cylinder >2D', 'incidence of adverse events', 'incidence of patient subjective symptoms', 'change in contrast sensitivity from preop to postop']","['Measured difference in manifest refraction between 2 postoperative visits', 'Calculated rate of change in manifest refraction', 'Calculated decreased rate of change in manifest refraction', 'Calculated stable rate of change in manifest refraction', 'Measured best corrected visual acuity (method 1)', 'Measured best corrected visual acuity (method 2)', 'Measured refractive cylinder', 'Incidence of adverse events', 'Incidence of patient reported visual phenomena', 'Measured contrast sensitivity']","['latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval', 'latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval', 'latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval', 'latter of 2 postoperative refractions performed at least 3 months apart or at 3 months after surgery when compared with the 1 month interval', '12 months', '12 months', '12 months', '12 months', '12 months', '12 months']",[],[],[],[],[],[],[],[],[],[],[],"['May 1, 2019']"
0,145,['NCT04423770'],[],"['Adult', 'Older Adult']",[],[],"['Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater anxiety.', 'Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater depressive symptoms.', ""Self-reports of infection control efforts in the respondents' primary dental practices"", 'Self-reports of personal protective equipment use']","['Anxiety', 'Depression', 'Dental practice infection control efforts', ""Dentists' use of personal protective equipment""]","['12 months', '12 months', '12 months', '12 months']",[],[],[],[],[],[],[],[],[],[],[],"['June 8, 2020']"
0,146,['NCT01358552'],[],['Adult'],[],[],[],['To determine overall patient satisfaction with Néevo®/NéevoDHA® using a 9-point satisfaction scale'],['Week 4'],[],[],[],[],[],[],[],[],[],[],[],['January 2011']
0,147,['NCT02856646'],[],"['Adult', 'Older Adult']",[],[],"['What are drivers of choice (eg. lack of response, safety, cost or other barriers to care) for:\n\ntreatment decisions across and between drug classes, changes and/or discontinuation in treatment, determinants of transplant eligibility/in-eligibility?']","['Health-related quality of life (HRQoL)', 'Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)', 'Drivers of Treatment Choice', 'Healthcare resource utilization measured by imputed costs', 'Grade of AE']","['Up to five years', 'Up to five years', 'Up to five years', 'Up to five years', 'Up to 5 years']","['BMS Clinical Trial Information', 'Investigator Inquiry Form', 'FDA Safety Alerts and Recalls']","['https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html', 'https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html', 'https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm']",[],[],[],[],[],[],[],[],[],"['September 21, 2016']"
0,148,['NCT01940679'],[],['Adult'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['September 2013']
0,149,['NCT02951598'],['H8A-US-B004'],"['Adult', 'Older Adult']",[],['Other Identifier'],[],"['Healthcare Resource Use by AD Cohort', 'Mean Economic Cost by AD Cohort', 'Bath Assessment of Subjective Quality of Life in Dementia (BASQID)', 'Mini-Mental State Examination (MMSE)', ""Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)"", 'Neuropsychiatric Inventory (NPI)', 'Functional Activities Questionnaire (FAQ)', 'Cognitive Function Inventory (CFI)', 'Zarit Burden Interview (ZBI)', 'Percentage of Participants with a Change in Living Situation', 'Time to Transition Across Stages of AD', 'Desire to Institutionalize Scale (DTI)']","['Baseline through Study Completion (36 Months)', 'Baseline through 24 Months', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', 'Baseline, End of Study (36 Months)', '36 Months', 'Baseline through Study Completion (36 Months)', 'Baseline through Study Completion (36 Months)']",[],[],[],[],[],[],[],[],[],[],[],"['October 29, 2016']"
0,150,['NCT02988934'],[],"['Adult', 'Older Adult']",[],[],[],['Outcomes of patients undergoing WATS sampling.'],['10 years'],[],[],[],[],[],[],[],[],[],[],[],['April 2016']
0,151,['NCT01028300'],[],['Adult'],[],[],[],"['Time to Return to Active Duty', 'No Re-operations, Revisions, Removals or Supplemental Fixation', 'No Implant Related Complications']","['24 months', '24 months', '24 months']",[],[],['Non-systematic Assessment'],[],['Skin and subcutaneous tissue disorders'],[],['EG000'],['1'],['4'],['1'],['Non-infected seroma'],['April 2010']
0,152,['NCT01034865'],"['76873', 'HEP0009']","['Adult', 'Older Adult']",[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['May 2001']
0,153,['NCT02352532'],[],"['Adult', 'Older Adult']",[],[],"[""The numeric pain rating scale (NPRS) will be used to assess the participant's pain levels. The participant will grade his/her pain on an 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain).The NPRS has been shown to be a reliable, generalizable, and internally consistent measure of clinical and experimental pain intensity in individuals with musculoskeletal disorders.33,34 A 2-point change on the NPRS is required to be clinically meaningful."", 'Participants with current LBP will undergo a standardized clinical examination based the Treatment Based Classification System.31 Patients without current LBP will undergo an abbreviated examination primarily focused on sociodemographic', 'The Oswestry Disability Index (ODI) is a LBP-specific subjective measure of disability. Users are asked to rate the difficulty of performing 10 functional tasks on a scale of 0 to 5 with different descriptors for each task. A total score out of 100 is calculated by summing each score and doubling the total. The answers provide a score between 0 and 100, with higher scores representing more disability. It has been shown to have excellent test-retest reliability (ICC2,1=.90), good validity, and superior responsiveness compared to other leading disability scales.32']","['Change in Numerical Pain Rating Scale', 'Change in function and disability utilizing a physical exam', 'Change in Oswestry Disability Index']","['7 days', '7 days', '7 days']",[],[],[],[],[],[],[],[],[],[],[],['January 2015']
0,154,['NCT03198793'],[],"['Adult', 'Older Adult']",[],[],"['Office blood pressure will be taken at Day 0, Visit 3, Visit 4, Visit 4.1, and Visit 5 (Day 56).', 'Office blood pressure will be taken at Day 0, Visit 3, Visit 4, Visit 4.1, and Visit 5 (Day 56).', 'Ambulatory blood pressure monitoring will be performed at Day 0 and Day 56.', 'Frequency and percentage of subjects who reach the level by the Week 8 (Day 56 Visit).', 'Identification of potential factors for responders, including baseline systolic blood pressure and diastolic blood pressure, gender, age, BMI, and others.']","['Change in office diastolic blood pressure from baseline to Week 8 (Day 56 Visit)', 'Change in office systolic blood pressure and diastolic blood pressure from baseline to Week 4 (Day 28 Visit)', 'Change in mean 24-hour ambulatory systolic blood pressure, diastolic blood pressure, and mean office blood pressure from baseline to Week 8 (Day 56 Visit)', 'Percentage of responders (defined as subjects with normalized office blood pressure, ie, less than or equal to 140-90 mmHg at Week 8 - Day 56 Visit)', 'Predictive factors for responders at Week 8 (Day 56 Visit)']","['8 weeks', '4 weeks', '8 weeks', '8 weeks', '8 weeks']",[],[],[],[],[],[],[],[],[],[],[],"['October 13, 2017']"
0,155,['NCT01112917'],[],"['Adult', 'Older Adult']",[],[],[],['Major Device-Related Adverse Events in Converted Subjects'],['6-months'],[],[],"['Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment', 'Non-systematic Assessment']",[],"['Blood and lymphatic system disorders', 'Blood and lymphatic system disorders', 'General disorders', 'Blood and lymphatic system disorders', 'Infections and infestations', 'Blood and lymphatic system disorders', 'General disorders']",[],"['EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000', 'EG000']","['4', '1', '13', '4', '3', '1', '57']","['149', '149', '149', '149', '149', '149', '149']","['4', '1', '13', '8', '3', '1', '89']","['Caval Thrombosis or Caval Occlusion', 'Compromise of Cardiac Valve Function due to Filter Embolization', 'Death', 'Deep Vein Thrombosis (DVT)', 'Infection, including access site infection', 'Pulmonary embolism', 'Other']",['December 2011']
0,156,['NCT01764269'],[],['Child'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],['January 2013']
0,157,['NCT03346603'],[],"['Adult', 'Older Adult']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],"['February 8, 2018']"
0,158,['NCT04281290'],[],"['Adult', 'Older Adult']",[],[],"['Disease-free survival is defined as the amount of time a subject survives without disease recurrence after treatment. Recurrence is defined as significant elevation of tumor markers Ca19-9 and CEA after operation (normal value of Ca19-9 is under 37.0 kU/L, normal value of CEA is under 4.2 µg/L). The appearance of one or more lesions on imaging investigation (US and/or CT) is also considered a recurrence.\n\nThe tumor markers and imaging investigations will be performed according to study protocol (tumor markers 1, 3, 6, 12 and 24 months after operation; imaging 1, 3, 6, 12, 18 and 24 months after operation - the imaging method will be CT or MR with or without contrast, with the exception of 1 and 18 months after the operation when an US will be performed).', 'Overall survival is defined as the amount of time a subject survives after therapy. Patient enrolled in the study will be followed up for at least five years. During first two years after surgery follow-up will be as written above, after that period patient will be followed-up according every 6 months.']","['Disease-free Survival', 'Overall Survival']","['1, 3, 6, 12, 18 and 24 months after operation', 'From the time of surgical treatment until 5 years after surgery']",[],[],[],[],[],[],[],[],[],[],[],"['March 1, 2020']"
0,159,['NCT04601103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,160,['NCT04600856'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,161,['NCT04599907'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,162,['NCT04593875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,163,['NCT04589507'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,164,['NCT04586205'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,165,['NCT04585646'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,166,['NCT04584788'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,167,['NCT04584099'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,168,['NCT04577898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,169,['NCT04577456'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,170,['NCT04569253'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,171,['NCT04567186'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,172,['NCT04562532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,173,['NCT04558970'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,174,['NCT04558632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,175,['NCT04558047'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,176,['NCT04557917'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,177,['NCT04557891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,178,['NCT04556968'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,179,['NCT04556474'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,180,['NCT04547920'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,181,['NCT04547712'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,182,['NCT04544670'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,183,['NCT04542525'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,184,['NCT04540913'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,185,['NCT04537013'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,186,['NCT04536168'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,187,['NCT04534764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,188,['NCT04532099'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,189,['NCT04529616'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,190,['NCT04529109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,191,['NCT04524247'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,192,['NCT04523545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,193,['NCT04513574'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,194,['NCT04510857'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,195,['NCT04508335'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,196,['NCT04502758'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,197,['NCT04501146'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,198,['NCT04500821'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,199,['NCT04499521'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,200,['NCT04496752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,201,['NCT04493021'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,202,['NCT04488666'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,203,['NCT04483791'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,204,['NCT04476784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,205,['NCT04474054'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,206,['NCT04469218'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,207,['NCT04466930'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,208,['NCT04455997'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,209,['NCT04455854'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,210,['NCT04450108'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,211,['NCT04437615'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,212,['NCT04422990'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,213,['NCT04419714'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,214,['NCT04409158'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,215,['NCT04403542'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,216,['NCT04400643'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,217,['NCT04394546'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,218,['NCT04388787'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,219,['NCT04388722'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,220,['NCT04386785'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,221,['NCT04378764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,222,['NCT04377438'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,223,['NCT04338971'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,224,['NCT04335981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,225,['NCT04332640'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,226,['NCT04330001'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,227,['NCT04324593'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,228,['NCT04320823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,229,['NCT04319887'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,230,['NCT04318132'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,231,['NCT04314947'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,232,['NCT04314700'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,233,['NCT04313725'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,234,['NCT04310566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,235,['NCT04307446'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,236,['NCT04306744'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,237,['NCT04305119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,238,['NCT04303273'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,239,['NCT04299386'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,240,['NCT04299009'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,241,['NCT04298359'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,242,['NCT04296773'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,243,['NCT04295499'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,244,['NCT04287036'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,245,['NCT04285541'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,246,['NCT04281940'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,247,['NCT04279522'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,248,['NCT04277455'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,249,['NCT04263532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,250,['NCT04252183'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,251,['NCT04247581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,252,['NCT04244357'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,253,['NCT04243369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,254,['NCT04243239'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,255,['NCT04239885'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,256,['NCT04237207'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,257,['NCT04236869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,258,['NCT04230486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,259,['NCT04224155'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,260,['NCT04223609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,261,['NCT04220060'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,262,['NCT04219891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,263,['NCT04211441'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,264,['NCT04210622'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,265,['NCT04207749'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,266,['NCT04206839'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,267,['NCT04206384'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,268,['NCT04203745'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,269,['NCT04202419'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,270,['NCT04201340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,271,['NCT04200898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,272,['NCT04196907'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,273,['NCT04195581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,274,['NCT04194307'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,275,['NCT04192630'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,276,['NCT04189913'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,277,['NCT04189081'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,278,['NCT04186806'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,279,['NCT04184973'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,280,['NCT04178720'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,281,['NCT04177771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,282,['NCT04177212'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,283,['NCT04176965'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,284,['NCT04175340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,285,['NCT04166032'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,286,['NCT04162652'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,287,['NCT04158466'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,288,['NCT04153292'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,289,['NCT04152642'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,290,['NCT04151992'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,291,['NCT04151290'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,292,['NCT04141007'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,293,['NCT04136158'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,294,['NCT04134286'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,295,['NCT04130490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,296,['NCT04127188'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,297,['NCT04121754'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,298,['NCT04119609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,299,['NCT04116879'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,300,['NCT04116866'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,301,['NCT04112784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,302,['NCT04112628'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,303,['NCT04112134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,304,['NCT04106934'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,305,['NCT04096495'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,306,['NCT04087395'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,307,['NCT04085328'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,308,['NCT04083742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,309,['NCT04082078'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,310,['NCT04081727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,311,['NCT04079842'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,312,['NCT04079816'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,313,['NCT04078490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,314,['NCT04073823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,315,['NCT04069585'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,316,['NCT04068818'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,317,['NCT04065659'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,318,['NCT04064606'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,319,['NCT04060524'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,320,['NCT04057105'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,321,['NCT04056494'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,322,['NCT04055519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,323,['NCT04055324'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,324,['NCT04054401'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,325,['NCT04046627'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,326,['NCT04043234'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,327,['NCT04040933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,328,['NCT04036747'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,329,['NCT04035161'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,330,['NCT04033315'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,331,['NCT04032977'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,332,['NCT04031989'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,333,['NCT04031976'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,334,['NCT04030702'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,335,['NCT04011826'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,336,['NCT04008836'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,337,['NCT04005586'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,338,['NCT04003831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,339,['NCT03999944'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,340,['NCT03997357'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,341,['NCT03996187'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,342,['NCT03995355'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,343,['NCT03992768'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,344,['NCT03991468'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,345,['NCT03972995'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,346,['NCT03971721'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,347,['NCT03969875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,348,['NCT03967184'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,349,['NCT03964831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,350,['NCT03953274'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,351,['NCT03950895'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,352,['NCT03949335'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,353,['NCT03944629'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,354,['NCT03942016'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,355,['NCT03941912'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,356,['NCT03934463'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,357,['NCT03934125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,358,['NCT03931213'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,359,['NCT03925545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,360,['NCT03920280'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,361,['NCT03918928'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,362,['NCT03912584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,363,['NCT03911700'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,364,['NCT03898778'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,365,['NCT03897751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,366,['NCT03897712'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,367,['NCT03895034'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,368,['NCT03888352'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,369,['NCT03872609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,370,['NCT03872466'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,371,['NCT03871179'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,372,['NCT03864848'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,373,['NCT03864081'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,374,['NCT03862300'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,375,['NCT03858140'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,376,['NCT03851510'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,377,['NCT03839199'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,378,['NCT03835026'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,379,['NCT03812679'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,380,['NCT03805074'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,381,['NCT03799549'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,382,['NCT03790046'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,383,['NCT03789669'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,384,['NCT03788551'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,385,['NCT03782116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,386,['NCT03779984'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,387,['NCT03771521'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,388,['NCT03771352'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,389,['NCT03764254'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,390,['NCT03748823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,391,['NCT03748771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,392,['NCT03748316'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,393,['NCT03748264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,394,['NCT03736798'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,395,['NCT03730480'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,396,['NCT03729024'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,397,['NCT03728309'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,398,['NCT03716492'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,399,['NCT03713281'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,400,['NCT03708393'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,401,['NCT03706430'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,402,['NCT03704636'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,403,['NCT03700372'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,404,['NCT03700047'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,405,['NCT03696316'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,406,['NCT03692741'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,407,['NCT03685136'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,408,['NCT03682432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,409,['NCT03681886'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,410,['NCT03681496'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,411,['NCT03678103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,412,['NCT03677388'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,413,['NCT03670277'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,414,['NCT03663010'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,415,['NCT03642431'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,416,['NCT03641937'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,417,['NCT03631550'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,418,['NCT03628898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,419,['NCT03617822'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,420,['NCT03614130'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,421,['NCT03613363'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,422,['NCT03611101'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,423,['NCT03604900'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,424,['NCT03604562'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,425,['NCT03604432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,426,['NCT03601182'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,427,['NCT03600194'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,428,['NCT03599271'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,429,['NCT03589911'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,430,['NCT03586167'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,431,['NCT03578302'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,432,['NCT03574259'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,433,['NCT03564366'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,434,['NCT03560141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,435,['NCT03550807'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,436,['NCT03540576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,437,['NCT03538561'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,438,['NCT03525704'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,439,['NCT03523208'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,440,['NCT03508778'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,441,['NCT03502200'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,442,['NCT03500341'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,443,['NCT03497910'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,444,['NCT03488849'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,445,['NCT03488238'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,446,['NCT03482297'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,447,['NCT03477370'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,448,['NCT03467204'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,449,['NCT03465514'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,450,['NCT03462576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,451,['NCT03451786'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,452,['NCT03442842'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,453,['NCT03441971'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,454,['NCT03441880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,455,['NCT03441477'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,456,['NCT03439189'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,457,['NCT03435224'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,458,['NCT03435211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,459,['NCT03431883'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,460,['NCT03423251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,461,['NCT03421145'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,462,['NCT03418545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,463,['NCT03408444'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,464,['NCT03388138'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,465,['NCT03384381'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,466,['NCT03372434'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,467,['NCT03372343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,468,['NCT03371160'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,469,['NCT03366194'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,470,['NCT03351192'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,471,['NCT03345121'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,472,['NCT03345017'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,473,['NCT03339388'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,474,['NCT03336944'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,475,['NCT03329794'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,476,['NCT03323515'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,477,['NCT03315117'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,478,['NCT03299933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,479,['NCT03275532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,480,['NCT03272308'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,481,['NCT03269097'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,482,['NCT03268356'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,483,['NCT03268265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,484,['NCT03267134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,485,['NCT03257410'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,486,['NCT03251079'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,487,['NCT03246503'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,488,['NCT03242148'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,489,['NCT03239574'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,490,['NCT03236519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,491,['NCT03235791'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,492,['NCT03233945'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,493,['NCT03230877'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,494,['NCT03230747'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,495,['NCT03219567'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,496,['NCT03198988'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,497,['NCT03190564'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,498,['NCT03182660'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,499,['NCT03172949'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,500,['NCT03150407'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,501,['NCT03148613'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,502,['NCT03147820'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,503,['NCT03147482'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,504,['NCT03147417'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,505,['NCT03143127'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,506,['NCT03142594'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,507,['NCT03142581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,508,['NCT03138369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,509,['NCT03138343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,510,['NCT03134989'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,511,['NCT03132363'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,512,['NCT03132350'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,513,['NCT03129152'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,514,['NCT03128840'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,515,['NCT03128632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,516,['NCT03127566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,517,['NCT03127540'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,518,['NCT03127527'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,519,['NCT03127501'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,520,['NCT03127488'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,521,['NCT03125135'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,522,['NCT03125122'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,523,['NCT03125109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,524,['NCT03125096'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,525,['NCT03125044'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,526,['NCT03124992'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,527,['NCT03124953'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,528,['NCT03124940'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,529,['NCT03124888'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,530,['NCT03124849'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,531,['NCT03124810'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,532,['NCT03124745'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,533,['NCT03124732'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,534,['NCT03124719'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,535,['NCT03124706'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,536,['NCT03124264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,537,['NCT03124251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,538,['NCT03123380'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,539,['NCT03123341'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,540,['NCT03122379'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,541,['NCT03120702'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,542,['NCT03100760'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,543,['NCT03098602'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,544,['NCT03073148'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,545,['NCT03072186'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,546,['NCT03066063'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,547,['NCT03038074'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,548,['NCT03035318'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,549,['NCT03034902'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,550,['NCT03021707'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,551,['NCT03021473'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,552,['NCT03019107'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,553,['NCT03017742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,554,['NCT03003767'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,555,['NCT02995421'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,556,['NCT02986789'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,557,['NCT02972892'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,558,['NCT02970799'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,559,['NCT02966210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,560,['NCT02957071'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,561,['NCT02956928'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,562,['NCT02948751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,563,['NCT02938637'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,564,['NCT02922621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,565,['NCT02919566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,566,['NCT02918942'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,567,['NCT02916823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,568,['NCT02913560'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,569,['NCT02911376'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,570,['NCT02910674'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,571,['NCT02907203'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,572,['NCT02904382'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,573,['NCT02888626'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,574,['NCT02872844'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,575,['NCT02870959'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,576,['NCT02870881'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,577,['NCT02863796'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,578,['NCT02863432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,579,['NCT02862080'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,580,['NCT02858089'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,581,['NCT02856490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,582,['NCT02849847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,583,['NCT02842970'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,584,['NCT02841397'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,585,['NCT02833571'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,586,['NCT02811328'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,587,['NCT02810080'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,588,['NCT02805933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,589,['NCT02805777'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,590,['NCT02800057'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,591,['NCT02799342'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,592,['NCT02799329'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,593,['NCT02795689'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,594,['NCT02787343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,595,['NCT02784431'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,596,['NCT02771119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,597,['NCT02764580'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,598,['NCT02761759'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,599,['NCT02756260'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,600,['NCT02746289'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,601,['NCT02746120'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,602,['NCT02719444'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,603,['NCT02716155'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,604,['NCT02712931'],['U1111-1180-4386'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,605,['NCT02711254'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,606,['NCT02699021'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,607,['NCT02698787'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,608,['NCT02698397'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,609,['NCT02697604'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,610,['NCT02686450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,611,['NCT02684110'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,612,['NCT02680964'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,613,['NCT02680860'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,614,['NCT02662049'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,615,['NCT02638883'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,616,['NCT02634996'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,617,['NCT02634554'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,618,['NCT02634125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,619,['NCT02631213'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,620,['NCT02626624'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,621,['NCT02624739'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,622,['NCT02622919'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,623,['NCT02599519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,624,['NCT02597296'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,625,['NCT02596464'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,626,['NCT02579486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,627,['NCT02576210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,628,['NCT02561052'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,629,['NCT02553395'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,630,['NCT02548429'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,631,['NCT02543814'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,632,['NCT02540577'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,633,['NCT02540564'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,634,['NCT02535234'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,635,['NCT02525783'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,636,['NCT02517645'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,637,['NCT02506400'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,638,['NCT02495116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,639,['NCT02480829'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,640,['NCT02474784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,641,['NCT02474771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,642,['NCT02474758'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,643,['NCT02458378'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,644,['NCT02455063'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,645,['NCT02441634'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,646,['NCT02436005'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,647,['NCT02430441'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,648,['NCT02405871'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,649,['NCT02403167'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,650,['NCT02396914'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,651,['NCT02388425'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,652,['NCT02383082'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,653,['NCT02380716'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,654,['NCT02380014'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,655,['NCT02365545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,656,['NCT02365467'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,657,['NCT02364375'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,658,['NCT02353377'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,659,['NCT02343068'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,660,['NCT02340832'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,661,['NCT02327598'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,662,['NCT02325609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,663,['NCT02322840'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,664,['NCT02312141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,665,['NCT02300974'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,666,['NCT02289534'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,667,['NCT02284321'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,668,['NCT02283125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,669,['NCT02280577'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,670,['NCT02275624'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,671,['NCT02272114'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,672,['NCT02271087'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,673,['NCT02268227'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,674,['NCT02255539'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,675,['NCT02239263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,676,['NCT02231034'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,677,['NCT02223663'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,678,['NCT02218450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,679,['NCT02195362'],['5R44HD039566'],[],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R44HD039566&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,680,['NCT02195128'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,681,['NCT02191800'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,682,['NCT02187458'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,683,['NCT02167880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,684,['NCT02166073'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,685,['NCT02142465'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,686,['NCT02142374'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,687,['NCT02142023'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,688,['NCT02141334'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,689,['NCT02134236'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,690,['NCT02124538'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,691,['NCT02108275'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,692,['NCT02089646'],['1059-14-SMC'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,693,['NCT02086812'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,694,['NCT02085174'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,695,['NCT02082847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,696,['NCT02070601'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,697,['NCT02036385'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,698,['NCT02020447'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,699,['NCT02006251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,700,['NCT02004249'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,701,['NCT02003105'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,702,['NCT01989390'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,703,['NCT01989377'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,704,['NCT01988727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,705,['NCT01988025'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,706,['NCT01984151'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,707,['NCT01973621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,708,['NCT01966211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,709,['NCT01957982'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,710,['NCT01951131'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,711,['NCT01950767'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,712,['NCT01940458'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,713,['NCT01940211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,714,['NCT01937000'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,715,['NCT01936987'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,716,['NCT01916083'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,717,['NCT01906736'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,718,['NCT01905241'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,719,['NCT01896141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,720,['NCT01894698'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,721,['NCT01883557'],['G030210'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,722,['NCT01882309'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,723,['NCT01877369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,724,['NCT01874925'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,725,['NCT01867008'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,726,['NCT01859975'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,727,['NCT01854879'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,728,['NCT01847846'],['MA07052013'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,729,['NCT01835769'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,730,['NCT01835366'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,731,['NCT01827488'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,732,['NCT01820741'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,733,['NCT01801995'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,734,['NCT01801241'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,735,['NCT01795807'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,736,['NCT01795118'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,737,['NCT01792869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,738,['NCT01790867'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,739,['NCT01787981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,740,['NCT01777880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,741,['NCT01773941'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,742,['NCT01773265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,743,['NCT01747265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,744,['NCT01738230'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,745,['NCT01738165'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,746,['NCT01733264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,747,['NCT01733251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,748,['NCT01724541'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,749,['NCT01721122'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,750,['NCT01715454'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,751,['NCT01700764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,752,['NCT01697813'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,753,['NCT01697774'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,754,['NCT01674400'],['DC83411'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,755,['NCT01670006'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,756,['NCT01662479'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,757,['NCT01660113'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,758,['NCT01658189'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,759,['NCT01652846'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,760,['NCT01643200'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,761,['NCT01640795'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,762,['NCT01630707'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,763,['NCT01629836'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,764,['NCT01627405'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,765,['NCT01614925'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,766,['NCT01613742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,767,['NCT01610505'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,768,['NCT01610349'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,769,['NCT01607606'],['5R44HL090055-03'],[],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R44HL090055-03&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,770,['NCT01604967'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,771,['NCT01597271'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,772,['NCT01591369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,773,['NCT01582386'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,774,['NCT01575210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,775,['NCT01564589'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,776,['NCT01560156'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,777,['NCT01558609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,778,['NCT01556750'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,779,['NCT01546831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,780,['NCT01546584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,781,['NCT01533831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,782,['NCT01533103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,783,['NCT01532752'],['DC83411'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,784,['NCT01532440'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,785,['NCT01524263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,786,['NCT01515618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,787,['NCT01513512'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,788,['NCT01499030'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,789,['NCT01494376'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,790,['NCT01480570'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,791,['NCT01476826'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,792,['NCT01473134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,793,['NCT01470079'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,794,['NCT01464580'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,795,['NCT01463618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,796,['NCT01462955'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,797,['NCT01450540'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,798,['NCT01443299'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,799,['NCT01443286'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,800,['NCT01442389'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,801,['NCT01436669'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,802,['NCT01436461'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,803,['NCT01414491'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,804,['NCT01414270'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,805,['NCT01412112'],['R44HD055019'],[],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R44HD055019&Fy=all'],['U.S. NIH Grant/Contract'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,806,['NCT01408017'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,807,['NCT01403584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,808,['NCT01392261'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,809,['NCT01379794'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,810,['NCT01374243'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,811,['NCT01370785'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,812,['NCT01367171'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,813,['NCT01365689'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,814,['NCT01358682'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,815,['NCT01336868'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,816,['NCT01313351'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,817,['NCT01313195'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,818,['NCT01311726'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,819,['NCT01307709'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,820,['NCT01297751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,821,['NCT01286792'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,822,['NCT01258400'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,823,['NCT01246115'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,824,['NCT01240733'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,825,['NCT01239576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,826,['NCT01234480'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,827,['NCT01230398'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,828,['NCT01201889'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,829,['NCT01194752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,830,['NCT01194739'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,831,['NCT01194726'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,832,['NCT01183195'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,833,['NCT01180257'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,834,['NCT01171066'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,835,['NCT01166607'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,836,['NCT01164527'],"['APT-0018 Rev D', 'HHSN272200800008C']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,837,['NCT01158963'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,838,['NCT01150227'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,839,['NCT01148251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,840,['NCT01147094'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,841,['NCT01145651'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,842,['NCT01145378'],['G060104'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,843,['NCT01143116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,844,['NCT01140919'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,845,['NCT01127347'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,846,['NCT01112475'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,847,['NCT01108822'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,848,['NCT01106222'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,849,['NCT01103869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,850,['NCT01100983'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,851,['NCT01098682'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,852,['NCT01097824'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,853,['NCT01092871'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,854,['NCT01077141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,855,['NCT01070992'],['RA-2009-081'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,856,['NCT01067040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,857,['NCT01062464'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,858,['NCT01062412'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,859,['NCT01062217'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,860,['NCT01057134'],['C-09-UP01'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,861,['NCT01043497'],['W81XWH-09-1-0441'],[],[],['Other Grant/Funding Number'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,862,['NCT01039064'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,863,['NCT01037439'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,864,['NCT01030588'],"['R44HL090055', 'IRB_336.07', 'IRB00000251']",[],['https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R44HL090055&Fy=all'],"['U.S. NIH Grant/Contract', 'Other Identifier', 'Other Identifier']",[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,865,['NCT01029028'],['09-0134'],[],[],['Other Identifier'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,866,['NCT01022554'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,867,['NCT01016236'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,868,['NCT01008202'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,869,['NCT01000454'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,870,['NCT00993772'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,871,['NCT00990483'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,872,['NCT00990210'],['VA IRB 02810'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,873,['NCT00986908'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,874,['NCT00981188'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,875,['NCT00979498'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,876,['NCT00979030'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,877,['NCT00969748'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,878,['NCT00968474'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,879,['NCT00961519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,880,['NCT00960947'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,881,['NCT00957632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,882,['NCT00957138'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,883,['NCT00956618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,884,['NCT00955331'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,885,['NCT00946075'],['IDE #G000180'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,886,['NCT00944411'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,887,['NCT00942942'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,888,['NCT00935974'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,889,['NCT00932789'],['RHUA01-008'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,890,['NCT00924716'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,891,['NCT00911040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,892,['NCT00906958'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,893,['NCT00906815'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,894,['NCT00906009'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,895,['NCT00905749'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,896,['NCT00903058'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,897,['NCT00901667'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,898,['NCT00900705'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,899,['NCT00889746'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,900,['NCT00878982'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,901,['NCT00877916'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,902,['NCT00865930'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,903,['NCT00865735'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,904,['NCT00863486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,905,['NCT00863447'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,906,['NCT00858091'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,907,['NCT00850434'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,908,['NCT00850109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,909,['NCT00846820'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,910,['NCT00843752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,911,['NCT00840619'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,912,['NCT00824018'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,913,['NCT00821769'],['RHUA01-007'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,914,['NCT00820040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,915,['NCT00819130'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,916,['NCT00818922'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,917,['NCT00810498'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,918,['NCT00810459'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,919,['NCT00809406'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,920,['NCT00806052'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,921,['NCT00802750'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,922,['NCT00800891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,923,['NCT00799981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,924,['NCT00794534'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,925,['NCT00791414'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,926,['NCT00790621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,927,['NCT00789334'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,928,['NCT00788450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,929,['NCT00788437'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,930,['NCT00782119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,931,['NCT00781651'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,932,['NCT00781222'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,933,['NCT00780065'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,934,['NCT00779623'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,935,['NCT00777283'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,936,['NCT00776893'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,937,['NCT00776815'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,938,['NCT00776152'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,939,['NCT00773903'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,940,['NCT00773721'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,941,['NCT00769340'],['G080082'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,942,['NCT00767910'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,943,['NCT00766727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,944,['NCT00764491'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,945,['NCT00764452'],['IDE G060049'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,946,['NCT00760643'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,947,['NCT00759694'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,948,['NCT00758979'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,949,['NCT00758875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,950,['NCT00758095'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,951,['NCT00756496'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,952,['NCT00754598'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,953,['NCT00748917'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,954,['NCT00748033'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,955,['NCT00747266'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,956,['NCT00739245'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,957,['NCT00732264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,958,['NCT00732134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,959,['NCT00728702'],['Grant-Michael J Fox Foundation'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,960,['NCT00727805'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,961,['NCT00727688'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,962,['NCT00726297'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,963,['NCT00726024'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,964,['NCT00725816'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,965,['NCT00725699'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,966,['NCT00716313'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,967,['NCT00690742'],['G070209'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,968,['NCT00681057'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,969,['NCT00680251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,970,['NCT00678808'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,971,['NCT00676546'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,972,['NCT00676078'],['G980023-CQA'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,973,['NCT00670137'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,974,['NCT00660556'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,975,['NCT00659139'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,976,['NCT00653211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,977,['NCT00639340'],['IDE G990139'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,978,['NCT00630526'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,979,['NCT00617630'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,980,['NCT00617162'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,981,['NCT00616226'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,982,['NCT00615342'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,983,['NCT00608647'],['G060186'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,984,['NCT00597571'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,985,['NCT00591513'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,986,['NCT00589069'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,987,['NCT00588601'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,988,['NCT00587613'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,989,['NCT00587509'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,990,['NCT00586456'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,991,['NCT00579176'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,992,['NCT00578513'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,993,['NCT00578487'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,994,['NCT00576953'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,995,['NCT00561847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,996,['NCT00542477'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,997,['NCT00529685'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,998,['NCT00506220'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,999,['NCT00448812'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,1000,['NCT00350259'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
